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Summary 
Hepatocellular carcinoma (HCC) is the one of the most prevalent and lethal cancer 
worldwide.  HCC is a difficult-to-treat tumor as suggested by the mortality figures 
which strictly coincide with incidence rates.  Mortality rates for HCC can reasonably 
be reduced by early detection or prevention. However, given the poor performance 
of existing therapies, strategies to prevent or delay tumor development in liver are 
urgently needed.  Mammalian target of rapamycin (mTOR) is a serine/threonine 
kinase that regulates cell proliferation and survival integrating mitogenic and nutrient 
signaling.  HCC is a complex and heterogeneous tumor with several genomic al-
terations.  There is evidence of aberrant activation of several signaling cascades 
such as mTOR signaling and p53/p21 pathway.  Therefore, the aim of this study 
was to determine the interaction between mTOR and p53/p21 signaling pathways in 
HCC and to find a new treatment to prevent this devastating disease. For this pur-
pose, an analogue of rapamycin, RAD001 was used.  This mTOR inhibitor was 
given to Fah- and Fah/p53- and Fah/p21-deficient mice.  The results from this study 
show that RAD001 treatment did not reduce liver injury produced by FAA accumula-
tion and did not affect baseline hepatocellular proliferation in healthy mice.  Interest-
ingly however, RAD001 efficiently inhibited proliferation of damaged hepatocytes 
and sustained their apoptosis sensitivity during chronic liver injury.  Additionally, 
RAD001 treatment significantly lowered p53 and/or p21 levels in Fah- and Fah/p21-
deficient mice indicating that activation of mTOR contributes to p53 accumulation in 
hepatocytes during chronic liver injury.  Furthermore, the ability of RAD001 to inhibit 
cell cycle was markedly attenuated in Fah/p53-deficient mice suggesting that p53 
pathway is required to suppress proliferation of hepatocytes with DNA damage.  
Mechanistically, RAD001 influenced the expression of several cell cycle related pro-
teins and the building of CDK-cyclin complexes involved in the transition from G0 to 
G1 phase of cell cycle.  Finally, long-term treatment with RAD001 noticeably de-
layed tumor development in liver.  
 
Keywords:  Liver, Cancer, mTOR 
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Zusammenfassung 
Hepatocellular Carcinoma (HCC) ist die weltweit am häufigsten auftretende und 
auch tödlichste Krebsform. HCC ist ein schwer zu behandelnder Tumor, was durch 
die Sterblichkeitsrate angedeutet wird, welche absolut mit der Rate der 
Neuerkrankungen korreliert. Die Sterblichkeitsrate durch HCC kann durch 
Früherkennung oder Prävention deutlich reduziert werden. Bedingt durch die 
schwache Wirkung bestehender Therapien, sind Strategien zur Vorbeugung oder 
Verzögerung der Tumorentwicklung dringend notwendig. Das Angriffsziel für 
Rapamycin (mTOR) ist bei Säugern eine Serin/Threonin Kinase, welche die Zell 
Proliferation und Überlebensintegrierende mitogene und nährende Signalisierung 
reguliert. HCC ist ein komplexer und heterogener Tumor mit verschiedenen 
genomischen Veränderungen. Hinweise deuten auf eine abweichende Aktivierung 
verschiedener Signalkaskaden hin, wie z.B. die mTOR Signalisierung und der 
p53/p21 Pfad. Das Ziel dieser Arbeit war es deshalb, die Interaktion zwischen 
mTOR und p53/p21 signalisierenden Pfaden in HCC zu bestimmen und eine neue 
Behandlung zur Vorbeugung dieser verheerenden Krankheit zu finden. Zu diesem 
Zweck wurde ein Analog von Rapamycin, RAD001, verwendet. Dieser mTOR 
Inhibitor wurde Fah-, Fah/p53- und Fah/p21- defizienten Mäusen verabreicht. Die 
Ergebnisse dieser Studie zeigen, dass die Behandlung mit RAD001, die durch FAA 
Anreicherung ausgelösten Leberschäden nicht reduziert. Jedoch hat RAD001 die 
basale hepato-zelluläre Proliferation in gesunden Mäusen nicht beeinflusst. 
Interessanterweise inhibierte RAD001 effizient die Proliferation geschädigter 
Hepatocyten  und anhaltend deren Sensitivität gegenüber Apoptose während 
chronischer Leberschädigung. Zusätzlich verringert RAD001 signifikant die Levels 
von p53 und/oder p21 in Fah- defizienten Mäusen. Diese Tatsache weist darauf hin, 
dass die Aktivierung von mTOR zur p53 Akkumulation in Hepatocyten während 
chronischer Leberschädigung beiträgt. Weiterhin wurde die Fähigkeit von RAD001, 
den Zellzyklus zu inhibieren, in Fah/p53- defizienten Mäusen merklich 
abgeschwächt. Das deutet darauf hin, dass der p53 Pfad zur Unterdrückung der 
Proliferation von Hepatocyten mit DNA Schädigung notwendig ist. RAD001 
beeinflusst die Expression verschiedener mit dem Zellzyklus verknüpften Proteine 
und den Aufbau von CDK-Cyclin Komplexen, welche in den Übergang von der G0 
Zusammenfassung 
 8  
in die G1 Phase des Zellzyklus involviert sind. Die Langzeitbehandlung mit RAD001 
hat schließlich die Tumorentwicklung in der Leber nachweislich verzögert. 
 
Schlagwörter:  Leber, Krebs, mTOR 
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Introduction 
Cancers arise by an evolutionary process as somatic cells mutate and escape the 
restraints that normally control their expansion.  Suppressing the emergence of 
such autonomous cells is an evolutionary imperative where cells in regenerative tis-
sues retain the potential for neoplastic disturbance throughout life.  Consequently, 
multiple mechanisms have arisen to anticipate uncontrolled cell division.  In combi-
nation, these tumor-suppressing mechanisms are remarkably effective. 
 
1.1 Hepatocellular Carcinoma 
Hepatocellular carcinoma is the most common type of liver cancer in adults, ac-
counting for 80% of all liver malignancies (Befeler and Di Bisceglie, 2002; Parkin et 
al., 2001). While many cancers may originate in other parts of the body and spread 
to the liver, HCC originates from hepatocytes. There are two different growth pat-
terns that occur in patients with HCC: as a single tumor that grows larger or as 
smaller cancer nodules throughout the liver, which grow into multiple tumors. 
 
Liver cancer is the sixth most common cancer and the third leading cause of can-
cer-related death worldwide. It is the major cancer in Southeast Asia and sub-
Sahara Africa, but the incidence of this tumor is much lower in Western Europe and 
the USA.  However, the incidence and mortality rates of HCC have doubled in the 
USA over the past 25 years, and this upward trend is expected to continue over the 
coming decades (El-Serag et al., 2003; El-Serag and Mason, 1999).  Each year, it is 
estimated that more than 700,000 people are diagnosed with liver cancer and over 
600,000 people die from the disease (Thorgeirsson and Grisham, 2002).  
 
The most common risk factor is a chronic hepatitis B (HBV) or C (HCV) infection. 
Cirrhosis, which is frequently caused by hepatitis, is associated with 50-80% of HCC 
patients (Liu et al., 2004).  However, other risk factors for HCC include race, cirrho-
sis from non-viral causes such alcoholism, hemochromatosis and primary biliary cir-
Introduction 
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rhosis.  Furthermore, concomitant risk factors such as HCV infection in addition to 
alcoholism, tobacco use, diabetes or obesity increase the relative risk of HCC de-
velopment, as numerous studies in humans and animal models have shown 
(Chokshi and Marrero, 2001; Davila et al., 2005; El-Serag et al., 2001; Fong et al., 
1994; Hassan et al., 2002; Ming et al., 2002; Ohata et al., 2003). 
 
HCV accounts for almost 90% of all cases of HCC in Japan; and in China, HBV in-
fection is diagnosed in about 80% of patients with HCC (Beasley, 1988; Di Bisce-
glie, 1995; El-Serag, 2002).  In Europe and North America, however, despite a sig-
nificant lower incidence rate of 3 to 4 per 100,000 population, a distinct increase in 
cases of HCC has been reported as a result of intravenous drug use, unsafe sexual 
practices and other causes (Allen and Venook, 2004; El-Serag and Mason, 1999; 
Wingo et al., 1995).  Because of a lack of effective HCV vaccination, underlying 
HCV infection is largely responsible for that increase.  As a result of the interval be-
tween the onset of infection and the development of liver cirrhosis, the incidence of 
HCV-related HCC will continue to increase over the next few years (Colombo and 
Donato, 2005).  In contrast to Asian populations, the percentage of Western pa-
tients with HCC but without underlying cirrhosis is considerable, and development of 
HCC in cirrhotic individuals in the West is associated with a wider spectrum of un-
derlying diseases. In the West, the percentage of virally engendered cirrhosis is 
lower than that in Asian regions, but alcohol-toxic or cryptogenic hepatic damage is 
observed more frequently in Western countries (Sherman, 2005).   
 
Patients with HCC are more likely to live longer when the cancer is detected before 
it has spread or if it is in the early stages (Bolondi et al., 2001; Llovet et al., 2003).  
The five-year survival rate for patients with resectable early stage cancer ranges 
from 30% to 60%. However, patients with advanced HCC have a five-year survival 
rate of less than 5%.  When HCC is detected in the early stages, surgery, local ab-
lation or liver transplantation are likely curative treatment options (Makuuchi and 
Sano, 2004; Shimozawa and Hanazaki, 2004).  On the other hand, current thera-
pies for tumors that have spread throughout the liver have not achieved the success 
rate that has been seen in several other tumors (Bruix and Sherman, 2005; Tang, 
2001).  Given the poor performance of existing therapies, strategies to prevent or 
reduce liver tumor development are urgently needed (Kensler et al., 2003).  
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HCC is a complex and heterogeneous tumor with several genomic alterations.  
There is evidence of aberrant activation of several signaling cascades such as the 
Wnt-ßcatenin pathway, EGFR-RAS-MAPKK pathway and c-Met pathway (Llovet 
and Bruix, 2008).  Among others, an increasing number of human diseases has 
been linked to the dysregulation of mTOR including diabetes, obesity and cancer 
(Kenerson et al., 2005; Um et al., 2004; Vellai et al., 2003).  Intriguingly, most of 
these are due to aberrant hyperactivity of the mTOR pathway, which makes inhibi-
tors of mTOR potentially effective therapeutics for the treatment of these diseases 
(Tsang et al., 2007).  Additionally, it has been shown that the p53/p21 pathway is 
altered in more that 50% of the human cancers.  Therefore, this study was focused 
to determine the interaction of mTOR and p53/p21 signaling pathways in the devel-
opment of tumors in the liver. 
 
1.2 Mammalian Target of Rapamycin (mTOR) signaling 
mTOR is a 250 kDa serine/threonine kinase that integrates mitogenic and nutrient 
signaling to regulate cell growth by controlling mRNA translation, ribosome bio-
genesis, autophagy and metabolism (Guertin and Sabatini, 2007).  mTOR is part of 
two large complexes: a rapamycin and nutrient-sensitive multiprotein complex called 
mTOR Complex 1 (mTORC1) (Hara et al., 2002; Kim et al., 2002; Loewith et al., 
2002) and a growth-factor-sensitive but nutrient-insensitive mTOR-containing com-
plex called mTOR Complex 2 (mTORC2).  Unlike mTORC1, rapamycin does not 
bind to mTORC2 (Jacinto et al., 2004; Loewith et al., 2002).  The discovery of 
mTORC2 provided conclusive evidence to the suspicions that rapamycin did not 
inhibit all of mTOR’s functions (Guertin and Sabatini, 2007). 
 
1.2.1 mTOR Complex 1 (mTORC1) 
This complex is characterized by functioning as a nutrient/energy/redox sensor and 
controlling protein synthesis.  It is activated by insulin, growth factors, amino acids 
and oxidative stress.  mTORC1 is composed of mTOR, regulatory associated pro-
tein of mTOR (RAPTOR), mammalian LST8/G-protein ß-subunit like protein 
(mLST8) and proline-rich Akt substrate 40 kDa (PRAS40) (figure 1) (Hara et al., 
Introduction 
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2002; Kim et al., 2002; Loewith et al., 2002; Sancak et al., 2007).  RAPTOR posi-
tively regulates mTOR activity and recruits mTORC1 substrates. On the other hand, 
PRAS40 negatively regulates mTOR activity in a manner that depends upon its 
phosphorylation state. The molecular function of mLST8 is still ambiguous (Hara et 
al., 2002; Sancak et al., 2007). 
 
1.2.1.1 Upstream regulation of mTOCR1 signaling 
A major understanding of mTOC1 regulation was reached by the discovery that the 
TSC1 and TSC2 bipartite protein complex negatively controls its activity (figure 1) 
(Crino et al., 2006).  Mutations in either the tsc1 or tsc2 gene cause the hamartoma-
tous syndrome tuberous sclerosis complex (TSC). The discovery of the connection 
between TSC and the mTORC1 pathway provided the first molecular link between 
mTOR and cancer (Guertin and Sabatini, 2007). TSC2 possesses a GTPase acti-
vating protein (GAP) activity and inactivation of the TSC1/2 complex, either by mu-
tation or by cellular growth signals, leading to the activation of the ras-like GTPase 
RHEB (Crino et al., 2006).  Although it is difficult to detect a direct biochemical in-
teraction between endogenous RHEB-GTP and mTORC1, in vitro experiments indi-
cate that soluble GTP-loaded RHEB directly activates the kinase activity of 
mTORC1.  In contrast, PRAS40 inhibits RHEB-GTP-dependent mTORC1 activation 
in a dose-dependent manner in an in vitro kinase assay, and it stably associates 
with mTORC1 in cells (Sancak et al., 2007).  Although RHEB-GTP and PRAS40 are 
adversaries in a cell-free system, in intact normal cells, Akt forces them to cooper-
ate.  For instance, Akt, and possible other kinases, phosphorylates PRAS40 on 
T246, diminishing its ability to inhibit mTORC1 (Huang and Porter, 2005; Kovacina 
et al., 2003; Sancak et al., 2007).  Therefore, Akt both promotes RHEB-GTP-
loading and relieves mTORC1 from PRAS40 repression. 
 
Growing evidence argues that the connection between Akt and TSC2-RHEB-
mTORC1 is a critical step in PI3K-meditated tumorigenesis.  For instance, rapamy-
cin slows the proliferation of transformed cells null for pten, a tumor suppressor 
gene,  or expressing constitutively active Akt (Guertin and Sabatini, 2005).  Studies 
in mouse models support this idea showing that the neoplastic phenotypes induced 
by pten deletion of transgenic activation of Akt are sensitive to rapamycin 
(Majumder et al., 2004; Neshat et al., 2001; Podsypanina et al., 2001).  In mice, de-
pletion of Akt activity can also thwart pten-deletion-driven as well as RAS-driven and 
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chemically induced tumorigenesis (Chen et al., 2006; Skeen et al., 2006).  Based on 
in vitro studies in mouse embryo fibroblasts, it is argued that the oncogenic activity 
of Akt in these models depends on mTORC1 (Skeen et al., 2006).   
 
In contrast to growth-factor-driven activation of mTORC1, hypoxia, AMPK activation 
resulting from depletion of cellular energy, Wnt-GSK3 signaling, and glucocorticoids 
all inhibit mTORC1 by promoting TSC1/2 activation (Inoki et al., 2006; Reiling and 
Sabatini, 2006; Wang and Proud, 2006).  Amino acid deprivation may also activate 
TSC1/2, although other evidence argues that mTORC1 and S6K1 respond to amino 
acid availability independently of TSC1/2 (Nobukuni et al., 2005; Sarbassov et al., 
2005a). 
 
 
 
 
Figure 1  The mTOR signaling 
The mTOR kinase is the catalytic component of two distinct multiprotein 
complexes called mTORC1 and mTORC2.  In addition to mTOR, mTORC1 
contains RAPTOR, mLST8, and PRAS40. mTORC1 drives cellular growth 
by controlling numerous processes that regulate protein synthesis and deg-
radation. Diverse positive and negative growth signals influence the activity 
of mTORC1, many of which converge upon the TSC1/2 complex. Activation 
and inhibition induced by direct phosphorylation is indicated by a phosphate 
(P) (Guertin and Sabatini, 2007). 
 
 
Introduction 
 22  
1.2.1.2 Downstream effectors of mTORC1 
Ribosomal p70 S6 kinase (S6K1) and eukaryotic translation initiation factor 4E 
(eIF4E)-binding protein 1 (4E-BP1), both regulators of mRNA translation, are the 
best characterized downstream effectors of mTOR as part of the mTORC1 complex 
(Bjornsti and Houghton, 2004).  mTOR-dependent phosphorylation of S6K1 allows 
translation of the translational apparatus (ribosomal proteins, elongation factors 
eEF1A, eEF2 and the poly-A-binding protein), whereas cap-dependent translation is 
regulated by phosphorylation of 4E-BP1 (Guertin and Sabatini, 2007).  When acti-
vated by mTORC1, S6K1 promotes protein synthesis by phosphorylating PDCD4 
(programmed cell death protein 4) and targeting it for degradation (Dorrello et al., 
2006).  PDCD4 blocks protein translation by binding and preventing the eIF-4A heli-
case from the unwinding secondary structure in the 5′ untranslated region (5’UTRs) 
of mRNA. The ribosomal protein S6 is perhaps the best-known S6K1 substrate.  S6 
is one of the 30 distinct ribosomal proteins, which together with 18S rRNA, consti-
tutes the smaller 40S ribosomal subunit.  The importance of S6 in ribosome function 
and protein translation is underlined by the deletion of S6 in mice, which results in a 
block of ribosome biogenesis and cell cycle progression (Tang et al., 2001).  De-
spite being an indirect measure of mTORC1 activity and lacking a clear function, S6 
phosphorylation is widely used in research and in the clinic as a biomarker of 
mTORC1 activity.  
 
The second established signaling pathway down-stream of mTOR is 4E-BP1. It is a 
small unstructured polypeptide that when hypophosphorylated binds to eIF-4E, it 
thereby prevents the formation of the eIF-4F complex and its binding to the cap of 
mRNA.  Structural studies indicate that 4E-BP proteins behave as molecular mimics 
of eIF-4G by competing for a binding to eIF-4E.  Upon phosphorylation by mTOR, 
4E-BP1 releases eIF-4E, which binds the cap at the 5’ ends of mRNA transcripts 
and assembles with other translation initiation factors to initiate cap-dependent 
translation (figure 1) (Guertin and Sabatini, 2007).  The cap consists of the structure 
m7GpppX (where X is any nucleotide). eIF-4F is a trimeric complex comprised of 
eIF-4G, eIF-4A and eIF-4E, that mediate the binding of the mRNA to the 43S pre-
initiation complex to form the 48S initiation complex.  eIF-4E binds directly to the 
cap structure.  eIF-4G is a scaffolding protein, which binds eIF-4A and eIF-4E.  eIF-
4A serves as an ATP-dependent helicase that functionally interacts with a cofactor, 
eIF-4B. eIF-4B is an initiation factor that promotes the binding of mRNA to 40S ri-
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bosomes in vitro and promotes ATP-dependent helicase activity of eIF-4A to unwind 
secondary structures present within the 5’UTRs of certain mRNAs, until the initiator 
AUG. eIF-4E appears to be the limiting factor in eIF-4F complex formation and to be 
highly regulated upon growth factor stimulation (Holland et al., 2004). 
 
The eIF-4F complex is thought to particularly enhance translation of transcripts pos-
sessing complex 5’-untranslated regions, which encode proteins associated with G1 
cell-cycle progression and S-phase initiation. Then inhibition of mTOR signaling 
may result in a prolonged G1 phase or arrest in G1. mTOR might therefore also be 
viewed as a gatekeeper, which only allows G1 progression under nutrient-replete 
conditions (Bjornsti and Houghton, 2004).  Interest in the regulation of mTOR has 
increased substantially in recent years, largely because of an apparent link between 
deregulation of translation and cancer cell survival (Shaw and Cantley, 2006). 
 
1.2.2 mTOR Complex 2 (mTORC2) 
Like mTORC1, mTORC2 also contains the mLST8 protein, but rather than 
RAPTOR, mTORC2 includes the rapamycin-insensitive companion of mTOR 
(RICTOR). This makes mTORC2 distinctive from mTORC1 due to the fact that 
mTORC2 does not likely bind to the rapamycin-FK506-binding protein 12 complex.  
In addition to mSIN1 (also known as mitogen-activated protein-kinase-associated 
protein 1) proteins, mTORC2 also contains the protein observed with RICTOR 
(PROTOR), a protein that is only found in higher eukaryotes (Pearce et al., 2007; 
Woo et al., 2007).  PROTOR specifically interacts with RICTOR, but not RAPTOR, 
because the interaction is tighter than the RICTOR-mTOR interaction and inde-
pendent of mTOR. 
 
The functions and regulatory mechanism of mTORC2 are still largely unknown.  It 
has been shown in several studies that mTORC2 should be considered as part of 
the PI3K-Akt pathway as it directly phosphorylates Akt on one of the two sites that 
are necessary for Akt activation in response to growth-factor signaling (Hresko and 
Mueckler, 2005; Sarbassov et al., 2005b).  Additional studies indicate that mTORC2 
regulates protein kinase C α phosphorylation, actin cytoskeleton organization, and 
Akt phosphorylation at Ser473 (Jacinto et al., 2004; Sarbassov et al., 2005b).  
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1.2.3 Negative feedback regulation of PI3K-Akt signaling 
Surprisingly, patients suffering from TSC do not develop more aggressive tumors 
like those patients suffering from diseases linked to pten mutations.  The reason for 
this difference may be the existence of a strong negative feedback loop.  In many 
cell types, PI3K-Akt signaling is strongly repressed upstream in the PI3K pathway 
by the activation of mTORC1 signaling (Manning, 2004).  It has been shown that 
loss of TSC1/2 function results in a decrease of Akt phosphorylation  (Jaeschke et 
al., 2002; Kwiatkowski et al., 2002).  Additionally, it appears that when mTORC1 is 
active, S6K1 directly phosphorylates and inhibits IRS1 (Zick, 2005).  When S6K1-
deficient mice are challenged with a high fat diet, they become resistant to obesity 
because loss of the feedback loop enhances their insulin sensitivity (Um et al., 
2004).  These data suggest that tumors in TSC patients are less aggressive be-
cause the feedback loop suppresses PI3K-Akt signaling.  
 
Mechanistically, when Akt is inactive, TSC1/2 inhibits RHEB while PRAS40 inhibits 
mTORC1 (figure 2, left). Upon activation, Akt promotes mTORC1 activity by phos-
phorylating both TSC1/2 and PRAS40, resulting in GTP-loading of RHEB, which 
directly activates mTORC1 and release of mTORC1 from PRAS40 repression (fig-
ure 2, middle).  When TSC is knocked down, RHEB strongly activates mTORC1 
and then Akt is inhibited by the negative feedback loop. Even though PRAS40 is 
dephosphorylated in this state, its ability to repress mTORC1 is overrun by the 
greatly elevated RHEB activity (figure 2, right) (Guertin and Sabatini, 2007). 
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Figure 2  Model of mTORC1 co-regulation by RHEB and PRAS40 
(Guertin and Sabatini, 2007) 
 
 
1.2.4 Role of mTOR in HCC 
Previous studies have shown that activation of the mTOR pathway in HCC ranged 
from 15% to 41% in experimental models of HCC (Sahin et al., 2004; Semela et al., 
2007).  A recent report showed that the mTOR pathway is activated in a subset of 
patients with early HCC.  That activation of mTOR signaling is due to ligand-
dependent signals from EGF and IGF signaling rather than from a mutation-
dependent mechanism.  Additionally, patients displaying activation of the mTOR 
pathway also presented higher levels of AFP, less differentiated tumors and a 
higher incidence of recurrence (Villanueva et al., 2008).  These data suggest the 
relevance of mTOR signaling in HCC and show it as an attractive target for clinical 
trials. 
 
1.3 RAD001 (Everolimus), a mTOR inhibitor 
As a sensor of the availability of growth factors, nutrients and energy sources, the 
mTORC1 kinase plays a central role in tumor biology.  Consequently, mTORC1 in-
hibitors have a broad antitumor activity as shown pre-clinically in experimental tumor 
models as well as clinically in cancer patients. Strikingly, certain tumor types appear 
to be predisposed to respond to mTORC1 inhibition, a phenomenon related to de-
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regulation of critical elements of the PI3K/mTORC1 pathway (Lane and Breuleux, 
2009).   
 
The macrolide antibiotic rapamycin is a product of the bacteria Streptomyces hygro-
scopicus, which was isolated from a soil sample taken from Easter Island (known 
locally as Rapa Nui). In the mid-1970s, it was identified as a potent antifungal agent 
and was found to be a potent suppressor of the immune system (Bjornsti and 
Houghton, 2004). 
 
Rapamycin and its analogues, like sirolimus (rapamycin), temsirolimus (CCI-779) 
and everolimus (RAD001), are highly specific inhibitors of mTOR, and differ only 
slightly in chemical structure that results in improved chemical stability and pharma-
ceutical properties.  Rapamycin first binds the 12-kDa immunophilin FK506-binding 
protein (FKBP12). The FKBP-rapamycin complex then binds to the FK-rapamycin 
binding (FRB) domain of mTOR, resulting in inhibition of the function of mTOR (fig-
ure 3).  Whether rapamycin or the FKBP-rapamycin complex directly inhibit the 
kinase activity of mTOR is controversial (Bjornsti and Houghton, 2004). This inhibi-
tion suppresses cytokine-driven T-cell proliferation, inhibiting the progression from 
G1 to the S phase of the cell cycle. 
 
 
 
Figure 3  Ribbon diagram of FKBP12 in complex with RAD001 
(Everolimus) interacting with the rapamycin-binding domain of mTOR.  
Red: Rapamycin-binding domain of mTOR; blue: FKBP12; pink RAD001  
 
 
RAD001 [40-O-2-hydroxyethyl)-rapamycin], or Everolimus, is an analogue of rapa-
mycin that can be administrated orally. The immunosuppressive activity of RAD001 
in vitro is about 3-fold lower than rapamycin, but its activity in vivo seems compara-
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ble to rapamycin due to some more favorable pharmacokinetic properties.  RAD001 
inhibits the growth factor-stimulated in vitro proliferation of vascular sooth muscle 
cells and prevents allograft rejection in rats (Schuler et al., 1997).  S6K1 inhibition 
and antineoplastic effect by RAD001 have been shown in human cancer cell lines in 
vitro and in xenograft models in vivo, an optimal effect being achieved with 2.5 
mg/kg/day in melanoma, lung, pancreas and colon carcinoma. Similarly, RAD001 
demonstrates a concentration-dependent anti-tumor activity in a rat pancreas carci-
noma model with an intermittent dosing schedule. RAD001 has also shown antian-
giogenic activity (Lane et al., 2009) and inhibits the human vascular endothelial cells 
proliferation.  RAD001 leads to an increase in the number of cells in the G0/G1 
phase of the cell cycle. At a concentration of 10nM, there was a 10-70% increase, 
indicating a delay in cell cycle progression at the early G0/G1 phase. An in vivo 
xenograft model confirmed this observation (Vignot et al., 2005).  When combined 
with other chemotherapeutic agents, RAD001 generally showed at least additive 
antitumor activity (Baselga et al., 2009; Sosman and Puzanov, 2009). 
 
RAD001 is currently undergoing evaluation in phase I studies as an anti-neoplastic 
agent and is already in phase III trials as an immunosuppressor acting in synergy 
with cyclosporine in kidney transplantation (Okamoto et al., 2009).   
 
1.4 p53  
The tumor suppressor p53 functions primarily as a transcription factor that can me-
diate its different downstream functions by activating or processing a large number 
of target genes (Mirza et al., 2003; Polyak et al., 1997; Vogelstein et al., 2000; Zhao 
et al., 2000).  p53 transcriptionally regulates a variety of biological activities 
(Vousden and Prives, 2009) that include DNA metabolism (Helton and Chen, 2007), 
apoptosis (Vousden, 2006), cell-cycle regulation (Kastan et al., 1992), senescence 
(Garbe et al., 2007), energy metablism (Green and Chipuk, 2006; Matoba et al., 
2006), angiogenesis  (Menendez et al., 2006; Pal et al., 2001; Teodoro et al., 2006; 
Zhang et al., 2000), immune response (Taura et al., 2008), cell differentiation, motil-
ity and migration (Molchadsky et al., 2008; Qin et al., 2009; Roger et al., 2006; 
Singh et al., 2007; Tedeschi and Di Giovanni, 2009), and cell-cell communication 
(Yu et al., 2006). Additionally, recent studies have demonstrated how p53-
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dependent activation of micro RNA genes can participate in the modulation of vari-
ous biological activities (Braun et al., 2008; He et al., 2007; Sinha et al., 2008; 
Yamakuchi et al., 2008). 
 
1.4.1 p53 in the cell cycle regulation 
p53 also induces cell-cycle arrest by stimulating the expression of the cyclin-
dependent kinase inhibitor p21 (p21).  This CDK inhibitor regulates the cell cycle via 
perturbation of cyclins which ensure the successful transitions from S phase to G1.  
CDKs inhibition by p21 results in suppression of both G1-to-S and G2-to-mitosis 
transitions by causing hypophosphorylation of retinoblastoma (Rb) and also pre-
venting the release of E2F.  Moreover, p53 can stimulate 14-3-3 protein which se-
questers the CDK1-cyclin B1 complex out of the nucleus, resulting in a G2 block 
(Zheng et al., 2006). 
 
1.4.2 Role of p53 in apoptosis 
Activation of p53 may not just induce cell-cycle arrest but also apoptosis.  Interest-
ingly, p53 regulates the expression of a key subset of the Bcl-2 family genes, in-
cluding Bax, Noxa, p53-upregulated modulator of apoptosis (PUMA) and BH3-
interacting domain death agonist (Bid). PUMA plays an important role in p53-
mediated apoptosis. In vitro, over-expression of PUMA is followed by increased Bax 
expression, Bax conformational change, translocation to the mitochondria, cyto-
chrome c release and reduction in the mitochondrial membrane potential (Liu et al., 
2003).  Noxa is also considered to be a mediator of p53-induced apoptosis.  It has 
been shown that Noxa can localize to the mitochondria and interact with anti-
apoptotic Bcl-2 family members, resulting in the activation of caspase-9 (Oda et al., 
2000).  Therefore, PUMA and Noxa might mediate the apoptosis that is elicited by 
genotoxic damage or oncogenes activation due to their expression is induced by 
p53.  Additionally, it has been reported that Myc oncoprotein potentiates apoptosis 
through both p53-dependent and p53-independent mechanisms (Meyer et al., 
2006). 
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1.4.3 p53 and its relation with the mTOR signaling 
Many studies have shown that there is a significant crosstalk at different levels be-
tween mTOR and p53 signaling. The p53 pathway is activated by cellular stress 
signals of DNA damage or hypoxia and results in cell-cycle arrest, senescence or 
apoptosis.  Dependent on p53 activation, the TSC1/TSC2 complex is activated di-
rectly or via positive regulation of the AMP kinase.  As a result, mTOR activity is 
suppressed, an effect reported also via activation of the LKB1 tumor suppressor 
identified upstream of AMP (Feng et al., 2007; Feng et al., 2005; Levine et al., 
2006; Shaw et al., 2004).  Higher upstream in the PI3K-Akt-mTOR pathway, p53 
positively regulates PTEN activity (Levine et al., 2006). 
 
1.4.4 p53 is mutated in many cancers 
The p53 pathway is crucial for effective tumor suppression. p53 is one of the most 
commonly mutated genes in human cancers. Mutational frequency of the p53 gene 
varies across tumor types but on average, 50% of all tumors will have sustained a 
lesion at the p53 locus. During tumorigenesis, the developing tumor cell is exposed 
to several cellular stresses that culminate in DNA damage. It may be likely that 
those tumors without p53 mutations have some lesions at points elsewhere in the 
p53 pathway, which would act to functionally inactivate the p53 response to DNA 
damage. ATM and MDM2 are examples of alternative targets for mutation that af-
fect p53 upstream of gene activation and can effectively prevent the transcription of 
downstream p53 target genes. This is also valid for mutation of genes downstream 
in the p53 pathway that would reduce the effectiveness of p53-mediated cell cycle 
arrest and apoptosis.  
 
Studies in animal models in which p53 has been constitutively or conditionally al-
tered demonstrate that p53 transcriptional activity is key to tumor suppression  
(Christophorou et al., 2006; Lozano, 2007; Martins et al., 2006).  Mouse knock-in 
approaches were used to show that the tissue-specific predisposition to cancer and 
tumor onset correlated with the DNA binding and transactivation potential of p53 
mutants in cell systems or in vitro (Iwakuma and Lozano, 2007; Liu et al., 2000; 
Ryan and Vousden, 1998). 
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1.4.5 p53 in Hepatocellular Carcinoma 
Mutations in p53 tumor suppressor gene are the most common alterations detected 
in HCC (Hussain et al., 2007).  It has been reported that p53 increases the fre-
quency of HCC prediction from 79% to 86% (El Far et al., 2006).  The existence of 
specific mutations in p53 in different human cancers involves environmental car-
cinogens and endogenous processes. For example, somatic mutations at the third 
base in codon 249 of p53 in HCC have been related to exposure to aflatoxin B1 
(AFB1), in association with HBV infection (Hussain et al., 2007).  Additionally, 
chronic infection with HBV and HCV viruses and exposure to oxidative stress induce 
DNA damage and mutation in cancer-related genes, including p53.  Thus, it can be 
considered that p53 mutations might operate in either HCC initiation or progression, 
depending of the context (Fabregat, 2009).  
 
A previous study showed that attenuated p53 function and telomere-induced chro-
mosomal instability play a critical and cooperative role in the progression of chronic 
liver damage to HCC (Farazi et al., 2006).  In vitro studies using human HCC-
derived cell lines showed that six of them show p53 abnormalities, suggesting that 
alterations in p53 may be important events in the transformation of hepatocytes into 
HCC (Nagao et al., 1999).  Additionally, p53 is often mutated in high-grade HCC 
(Jeng et al., 2004).  It has been shown that loss of p53 occurs in HCC and diversity 
of the p53 aberrations increases with the progression of chronic liver damage to 
HCC (Guan et al., 2007). 
 
1.5 p21  
During evolution, higher eukaryotes have evolved different checkpoint mechanisms 
in order to monitor and respond to cellular stresses, arresting cell proliferation until 
the errors are fixed or the environmental conditions become proper to transmit the 
genetic material.  When these checkpoints are disturbed, the integrity of the ge-
nome is compromised and cancer development could be promoted.  The tumor 
suppressor protein p53 mediates the DNA-damage-induced checkpoint through the 
activation of numerous growth inhibitory or apoptotic genes.  Among these, the 
small 165 amino acid protein p21 mediates p53-depenent G1 cell-cycle arrest 
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(Brugarolas et al., 1995; Deng et al., 1995).  p21 belongs to the Cip/Kip family of 
CDK inhibitors that includes p21, p27 and p57.  p21 primarily binds and inhibits the 
kinase activity of the CDK2 and CDK1, inducing growth arrest at specific stages in 
the cell cycle (figure 4).    
 
 
 
Figure 4  p21 promotes and inhibits the kinase activity of several 
CDK/cyclin complexes   
Under determined conditions, the cell-cycle progression through G1 is pro-
moted by p21, which advocates the kinase activity of CDK4 or CDK6 in a 
complex with cyclin D.  p21 also suppresses E2F1-dependent gene tran-
scription and progression into and through the S phase by inhibiting CDK2-
cyclin E and the subsequent inhibition of CDK2-dependent phosphorylation 
of Rb and the sequestration of E2F1.  In addition, p21 suppresses the 
kinase activity of CDK2-cyclin A and CDK1-cyclin A, which are needed for 
progression through the S phase and into G2 respectively.  Furthermore, 
p21 inhibits the progression through G2 and G2/M by suppressing the 
kinase activity of CDK1-cyclin B1 (Abbas and Dutta, 2009). 
 
 
Furthermore, p21 binds to the proliferation cell nuclear antigen (PCNA), interfering 
with its PCNA-dependent DNA polymerase activity and thereby inhibiting DNA repli-
cation and modulating numerous PCNA-dependent DNA repair processes (figure 
5). 
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p21 was considered initially as a potential tumor suppressor since it inhibits prolif-
eration and is the major downstream target of p53. However, evidence from recent 
studies suggests that, under certain conditions, p21 could also act as an oncogene 
due to its role in apoptosis (Gartel, 2009). 
 
 
Figure 5  p21 inhibits PCNA 
p21 binds to and inhibits PCNA and then suppresses the DNA synthesis and 
modulation of PCNA-dependent DNA repair pathways (Abbas and Dutta, 
2009). 
 
 
1.5.1 p21 as a tumor suppressor 
Tumor suppressor functions for p21 were found in p21-null mice that develop a va-
riety of neoplasias that include tumors of hematological, endothelial and epithelial 
origin. Additionally, p21 could protect mice against chemical carcinogens because 
its loss greatly accelerated the development of malignant skin carcinoma induced 
by chemicals (Topley et al., 1999).  Furthermore, the absence of p21 mainly re-
sulted in higher grade, poorly differentiated tumors in a skin carcinogenesis mouse 
model (Philipp et al., 1999).   
 
It has been shown that p21 alone is sufficient to suppress the regenerative capacity 
of hepatocytes and kidney proximal tubular cells. Loss of p21 is not compensated 
by other cell-cycle inhibitors. In its absence, proliferation of cells with DNA damage 
resulted in rapid cancer formation (Willenbring et al., 2008a). By mediating p53-
dependent cell-cycle arrest, p21 plays a significant role in tumor suppression since 
the absence of p21 makes mice more susceptible to tumorigenesis (Martin-
Caballero et al., 2001). 
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1.5.2 Oncogenic activities of p21 
In contrast to the tumor suppression functions, p21 may also act as an oncogene.  
In p53-deficient mice, loss of p21 results in a significantly extended survival of the 
animals (De la Cueva et al., 2006).  Additionally, loss of p21 in Atm-deficient mice 
delays thymic hymphomagenesis. In mouse models for oligodendrogliomas 
(ODGs), loss of p21 reduced the development of tumors (Miettinen et al., 2001).   
 
Specifically in liver, studies have shown that p21 checkpoint activation was associ-
ated with an increased HCC risk at the cirrhosis stage (Wagayama et al., 2002).  
Additionally, other studies present evidence that telomere shortening and an accu-
mulation of DNA damage, molecular characteristics of HCC, coincide with loss of 
p21 (Plentz et al., 2007).  Moreover, p21 is overexpressed in other cancers such as 
prostate, cervical, breast and squamous cell carcinomas; and p21 upregulation cor-
relates positively with tumor grade, invasiveness and aggressiveness and is a poor 
prognostic indicator, suggesting that p21 may also act as an oncognene (Abbas 
and Dutta, 2009). 
 
1.5.3 p21, a modulator of apoptosis 
Although best known for its growth-inhibitory functions, p21 also inhibits apoptosis.  
Through its ability to promote cell-cycle inhibition, especially in the face of genotoxic 
insults or microtubule-destabilizing agents, p21 protects cells from apoptosis be-
cause an active cell cycle is required to sense these agents and trigger apoptosis.  
The cytostatic effect of p21 with the consequent inhibition of apoptosis is counter-
acted by several mechanisms. The cellular response can be switched from cell-
cycle arrest to apoptosis by the selective transcriptional repression of CDKN1A, the 
selective activation of pro-apoptotic genes or defects in p21 expression downstream 
of p53 (Kaneuchi et al., 1999; Okaichi et al., 1999; Samuels-Lev et al., 2001). Addi-
tionally, post-transcriptional modifications of p21 such as its phosphorylation (Li et 
al., 2002; Meng et al., 2007; Oh et al., 2007), which affects protein stability or cyto-
plasmatic localization of p21 (Li et al., 2002; Zhou et al., 2001), and its cleavage by 
caspase-3 also account for the differential effects on cell-cycle arrest versus apop-
tosis (Zhang et al., 1999). 
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p21 also can protect against apoptosis in different stimuli such as those induced by 
growth factor deprivation or p53 overexpression (Roninson, 2002).  Under these 
conditions, the anti-apoptotic effect of p21 cannot be attributed to its cytostatic ef-
fects because apoptosis does not depend on cell-cycle progression.  Rather, it may 
depend on the ability of p21 to regulate gene transcription through its multiple pro-
tein-protein interactions or its function in DNA repair.  For example, when p21 is lo-
calized in cytoplasm, it binds to and inhibits the activity of protein involved in the in-
duction of apoptosis (procaspase-3 and caspase-8), stress-activated kinases 
(SAPKs) and apoptosis signal-regulating kinase 1 (ASK1) (figure 6) (Dotto, 2000; 
Roninson, 2002).  Additionally, p21 induces the upregulation of genes encoding 
anti-apoptotic proteins, and suppresses the induction of pro-apoptotic genes (Dotto, 
2000). 
 
 
 
Figure 6  Cytoplasmic activity of p21 
Nuclear translocation of p21 is inhibited when phosphorylated at Thr145 by 
activated Akt1 downstream of ERBB2 or IKKß signaling.  At the cytoplasm, 
p21 exhibits anti-apoptotic activity, inhibiting several proteins involved in 
apoptosis.  It is not clear whether the phosphorylation of p21 is only required 
for retaining p21 in the cytoplasm or also for its cytoplasmic activities. ASK1, 
apoptosis signal-regulating kinase 1, also known asSAPK, stress-activated 
protein kinase (Abbas and Dutta, 2009). 
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1.6 Hereditary Tyrosinemia type 1 
The liver plays a central role in the pathophysiology of many inborn errors of me-
tabolism, because it is the major site of catabolic, synthetic and detoxification reac-
tions.  In humans, the most severe disease of the tyrosine catabolic pathway is He-
reditary Tyrosinemia type 1 (HT1), an autosomal recessive inborn error of metabo-
lism.  The first report with typical clinical and biochemical findings was presented by 
Sakai in 1957 (Pitkanen et al., 2000).  This disease is characterized by progressive 
liver and kidney damage and neurological crisis.  In the acute form, symptoms ap-
pear in early childhood and are characterized by a rapid deterioration of hepatic and 
renal functions, leading to death during the first year because of liver failure. The 
chronic form includes symptoms such as progressive hepatic dysfunction during 
infancy and death from liver cirrhosis or HCC. Cardiomyopathy is also a common 
feature of the disorder (Langlois et al., 2006). 
 
HT1 is caused by deficiency of the enzyme fumarylacetoaccetate hydrolase (FAH), 
which carries out the last step in the tyrosine catabolic pathway (figure 7). This en-
zyme is a homodimer of two 43 kDa subunits, consisting of 419 amino acids resi-
dues per monomer (Pitkanen et al., 2000).  The absence of FAH leads to an accu-
mulation of the primary metabolite in HT1, fumarylacetoaccetate (FAA), maleylace-
toacetate (MAA), succinylacetone (SA) and tyrosine.  It has been shown that FAA, 
but not MAA nor SA, is highly mutagenic and a potent alkykator, causing oxidative 
damage by reacting with glutathione and sulfhydryl groups of proteins. FAH is 
mainly expressed in the liver and in the kidneys (Grompe, 2001).   
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Figure 7  Schematic tyrosine catabolic pathway 
Three types of hereditary Tyrosinemia have been described (HT).  In HT1 
fumarylacetoacetase (FAA) is defective.  This defect in FAA activity leads to 
the accumulation of toxic metabolites. The enzymes that are involved in the 
pathway are shown in blue. They are: Tyrosine aminotransferase, 4-
hydroxyphenylpyruvate dioxygenase, homogentisic acid oxidase, and maley-
lacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia type 
1. NTBC was used in this study as an inhibitor of 4-hydroxyphenylpyruvate 
dioxygenase. 
 
 
Prevention of FAA accumulation has beneficial therapeutic effects in HT1.  A dietary 
restriction in tyrosine and phenylalanine is given to HT1 patients to limit the accumu-
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lation of the toxic metabolite FAA. However, treatment with NTBC (2-(2-nitro-4-
fluoromethylbenzoyl)-1,3-cyclohexanedione) has become the mainstay for the man-
agement of HT1.  The principle of this treatment is to reduce metabolic flow through 
the tyrosine catabolic pathway by blocking the activity of 4-hydroxyphenylpyruvate 
dioxygenase (HPD), enzyme acting upstream of FAH in the tyrosine catabolic path-
way, preventing the formation of the toxic compound FAA (figure 7).  NTBC rapidly 
improves liver and kidney functions but does not completely prevent the formation 
of HCC in long-term therapy (Al-Dhalimy et al., 2002). 
 
Alternative causes of elevated concentration of plasma tyrosine exist and are attrib-
utable to genetic defects different than those responsible for tyrosinemia type I.  
These have been categorized as tyrosinemia type II and tyrosinemia type III. Each 
of these two disorders are more benign than type I, with different clinical presenta-
tions. Tyrosinemia type II is caused by a deficiency of tyrosine aminotransferase 
(TAT) and clinically presents with hyperkeratotic plaques on the hands and soles of 
the feet and affected individuals may have photophobia.  Tyrosinemia type III is an 
extremely rare disorder, caused by a deficiency of 4-hydroxyphenylpyruvic dioxy-
genase (HPD), and is associated with metabolic acidosis and growth failure in in-
fancy (Russo et al., 2001).   
 
Importantly, tyrosine per se is not toxic to the liver or kidney but rather causes only 
dermatological, ophthalmologic, and possible neurodevelopmental problems.  Pa-
tients with Tyrosinemia type II and III have highly elevated blood tyrosine levels but 
do not manifest liver disease or renal tubular dysfunction (Grompe, 2001). 
 
1.7 Murine Hepatic Cancer Model  
A murine model of Fah deficiency has been developed by targeted disruption of 
exon 5 of the Fah gene (Grompe et al., 1993).  Homozygous mutant mice die in the 
neonatal period due to hepatic dysfunction. Fah-deficient mice have a grossly al-
tered pattern of hepatic mRNA expression, particularly in genes responsive to 
cAMP, they suffer from severe hypoglycemia, and the endoplasmic reticulum of 
hepatocytes is disorganized.  The neonatal lethality and misexpression of liver 
mRNA in Fah-deficient mice can be rescued by the drug NTBC.  When NTBC 
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treatment is stopped in adult Fah-deficient mice, they develop a phenotype similar 
to humans with HT1, including rapidly progressive hepatic dysfunction and death 
within 2 months after drug withdrawal (Overturf et al., 1996).  Low-dose treatment 
with NTBC causes less liver injury, allowing the survival of the mice.  However, all of 
these mice develop liver cancer.  The hepatocytes undergo progressive malignant 
changes from dysplasia to hepatomas and then to HCC,  thus providing the oppor-
tunity to study the molecular changes associated with tumor progression in the liver 
(Grompe et al., 1995). 
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2 Aim of the Study 
The aim of this study was to determine the interaction between mTOR and p53/p21 
signaling pathways that are implicated in hepatocellular carcinogenesis and to find a 
new treatment to prevent this devastating disease. For this purpose, an analogue of 
rapamycin, RAD001, was used.  This mTOR inhibitor was given to Fah-, Fah/p53- 
and Fah/p21-deficient mice. 
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3 Materials and Methods 
3.1 Mice 
In this study, the C57BL/6-Fahtm1Mgo (Fah-/-) mouse strain was used (Grompe et al., 
1993). Fah-/- mice were crossed with C57BL/6-p21tm1 (p21-/-) and C57BL/6J-Tg(Alfp-
cre)1Gsc - FVB.129-Trp53tm1Brn (p53fl/fl/Alfp-Cre+) mice through successive genera-
tions to produce C57BL/6-Fahtm1Mgo - C57BL/6-p21tm1 (Fah/p21-/-) and C57BL/6-
Fahtm1Mgo  - C57BL/6J-Tg(Alfp-cre)1Gsc - FVB.129-Trp53tm1Brn (Fah-/-/p53fl/fl/Alfp-Cre, 
i.e., Fah/p53-/-) mice double knockout mice. Alfp-cre mediated deletion in p53 mice 
is hepatocyte-specific. Those mice express the cre-recombinase open frame (ORF) 
under the control of both the mouse albumin regulatory elements and the alpha-
fetoprotein enhancers (Alfp-cre) (Kellendonk et al., 2000). 
 
Animals were monitored by two inspections per week. All Fah-deficient animals 
were treated with NTBC in the drinking water at a concentration of 7.5mg/L unless 
otherwise indicated (a gift from S. Lindstedt, Gøtheborg, Sweden). C57BL/6 wild-
type mice were purchased from Jackson Laboratories.   
 
Bromodeoxyuridine (BrdU) was given to the mice in drinking water at a concentra-
tion of 0.8mg/ml for 4 days before liver collection, unless otherwise indicated. 
 
Mice were housed in rooms with constant temperature, humidity and 12h light/dark 
cycles. Food and water were available ad libitum. Animal care and experiments 
were all in accordance with the guidelines of the department of animal care at Han-
nover Medical School, Hannover, Germany. 
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3.2 Genotyping 
3.2.1 DNA isolation from mouse tails 
Three millimeter mouse tails were lysated in a buffer (10mM Tris-HCl pH 8.2, 
400mM NaCl, 2mM EDTA), containing 2% SDS and 50U/ml proteinase K, overnight 
at 56°C. The next day, proteinase K was inactivated  by heating for 10min at 96°C. 
Saturated NaCl was added to lysates and centrifuged for 10min at maximum speed. 
Finally, supernatant was taken and diluted by a ratio of 1:10 with distilled/deionized 
water. 
 
3.2.2 Genotyping of Fah mice 
Three primers were used for Fah genotyping: 
066 – Forward primer 5’- CTA GGT CAA TGG CTG TTT GG -3’ 
067 – Common primer 5’- GGA CAT ACC AAT TTG GCA AC -3’ 
068 – Reverse primer 5’- TAA AAT GAG GAA ATT GCA TCG -3’ 
 
The PCR conditions were as follows: 2.5µl 10x reaction buffer (Genecraft), 0.5µl 
2mM dNTPs, 1µl 10pmol primers, 0.5µl 5 units/µl Biotherm Taq DNA polymerase 
(Genecraft), 2µl 1:10 diluted DNA and 11.5µl distilled water. The PCR profile was as 
follows: initial denaturation at 94°C for 2min., th en for cycling, denaturation at 94°C 
for 40sec, annealing at 62°C for 1min and extension  at 72°C for 1min. Thirty-four 
cycles of PCR amplification and a final extension step at 72°C for 10min were per-
formed.  PCR products were run in a 1% agarose gel containing 1.5µl Gel Star Nu-
cleic Acid Gel Stain (Lonza) per 100ml agarose gel. The primers amplified a frag-
ment of 180bp for Fah+/+ and 240bp for Fah-/- and both fragments for Fah+/-. 
 
3.2.3 Genotyping of p21 mice 
For p21 genotyping, three primers were used:  
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PGK neo – 5’- GAA GAA CGA GAT CAG CAG -3’ 
p21 exon 144 – 5’- GAA CTT TGA CTT CGT CAG GG -3’ 
p21 geno U – 5’- ACA ACA CCT CCT GGT CAG AGG -3’ 
 
The PCR conditions were as follows: 5µl 5x Go Taq reaction buffer (Promega), 2µl 
2mM dNTPs, 1µl 10pmol primers, 0.2µl 5 units/µl Go Taq DNA polymerase 
(Promega), 2µl 1:10 diluted DNA and 12.8µl distilled water. The PCR profile was as 
follows: initial denaturation at 95°C for 2min., th en for cycling, denaturation at 95°C 
for 30sec, annealing at 62.5°C for 30sec and extens ion at 72°C for 1min. Thirty-five 
cycles of PCR amplification and a final extension step at 72°C for 5min were per-
formed.  PCR products were run in a 1% agarose gel containing 1.5µl Gel Star Nu-
cleic Acid Gel Stain (Lonza) per 100ml agarose gel. The primers amplified a frag-
ment of ~700bp for p21+/+ and ~100bp for p21-/- and both fragments for p21+/-. 
 
3.2.4 Genotyping of p53 Alfp-cre mice 
The following pair primers were used for p53 genotyping:  
p53 A – 5’- CAC AAA AAC AGG TTA AAC CCA G -3’ 
p53 B – 5’- AGC ACA TAG GAG GCA GAG AC -3’ 
 
The PCR conditions were as follows: 2µl 10x reaction buffer (Genecraft), 2.5µl 2mM 
dNTPs, 1µl 10pmol primers, 2µl 25mM MgCl2, 0.2µl 5units/µl Biotherm Taq DNA 
polymerase (Genecraft), 2µl 1:10 diluted DNA and 9.3µl distilled water. The PCR 
profile was as follows: initial denaturation at 94°C for 2min., then for cycling, denatu-
ration at 94°C for 30sec, annealing at 61°C for 30s ec and extension at 72°C for 
50sec. Thirty-five cycles of PCR amplification and a final extension step at 72°C for 
5min were performed.  PCR products were run in a 1% agarose gel containing 1.5µl 
Gel Star Nucleic Acid Gel Stain (Lonza) per 100ml agarose gel. The primers ampli-
fied a fragment of 288bp for p53+/+ and 370bp for p53Lox/Lox and both fragments for 
p53+/Lox. 
 
For Alfp-cre genotyping, the following pair primers were used: 
Alfp-cre1 – 5’- GGA AAT GGT TTC CCG CAG ACC -3’ 
Alfp-cre2 – 5’- ACG GAA ATC CAT CGC TCG ACC -3’ 
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The PCR conditions were as follows: 2.5µl 10x reaction buffer (Genecraft), 0.5µl 
2mM dNTPs, 1µl 10pmol primers, 2µl 25mM MgCl2, 0.2µl 5units/µl Biotherm Taq 
DNA polymerase (Genecraft), 2µl 1:10 diluted DNA, 10.8µl distilled water. The PCR 
profile was as follows: initial denaturation at 95°C for 2min., then for cycling, denatu-
ration at 95°C for 40sec, annealing at 62°C for 1mi n and extension at 72°C for 
1min. Thirty-four cycles of PCR amplification and a final extension step at 72°C for 
10min were performed.  PCR products were run in a 1% agarose gel containing 
1.5µl Gel Star Nucleic Acid Gel Stain (Lonza) per 100ml agarose gel. The primers 
amplified a fragment of ~500bp for Alfp-cre+. 
 
3.3 RAD001 (Everolimus) 
RAD001, a rapamycin analogue, was provided by Novartis Pharma AG. RAD001 
was formulated at 2% (w/v) in a microemulsion vehicle, which was diluted to the ap-
propriate concentration in water just before administration by gavage. Different 
doses of RAD001 were tested; 10 mg/kg/day were subsequently used for the ex-
periments.  
 
3.4 Collection of samples 
Shortly, mice were narcotized with a 10% ketamine/0.04% xylazine solution 
(12.5µl/g mouse). The abdomen cavity was longitudinally incised and the outer and 
inner skin was turned on one side and then to the other, so as to obtain an exami-
nation field as wide as possible.  The complete liver was removed from the mouse. 
 
3.4.1  Mouse liver collection 
After taking out the liver from the mouse, it was split into parts and stored as fol-
lows: Left lateral, caudate lobes and half of the median lobe were frozen in liquid 
nitrogen and kept at -80°C for protein analysis. Th e other half of the median lobe 
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was fixed in formalin and embedded in paraffin. The right lobe was embedded in 
OCT and kept at -20°C (figure 8). 
 
 
 
Figure 8  Mouse liver lobes 
 
 
3.4.2 Mouse blood collection and serum measurements 
Mice blood was taken from the orbital sinus using a glass capillary tube, collected in 
tubes containing heparin (Li-heparin LH/1.3 ml, Sarstedt) and processed as per 
manufacturer instructions. Bilirubin and glucose levels and transaminase activity 
were measured using an Olympus AU 400 System. 
 
3.5 Western blot analysis 
Liver tissue was homogenized in a cell lysis buffer (Cell Signaling) containing 1X 
Complete Protease Inhibitor mixture (Roche, Mannheim, Germany), centrifuged for 
10min at 16000xg. Protein quantification was done from the supernatant by adding 
Bio-Rad Protein Assay Dye Reagent (80µl of 1:3000 protein extract/distilled water to 
20µl reagent) and measuring OD at 595nm in a photometer. Then, 100µg protein 
extracts containing an electrophoresis sample buffer (4x ESB: 0,5M Tris Base, 40% 
glycerol, 12% SDS, 0,08% w/v bromophenol blue, 20% ß-mercaptoethanol) were 
resolved by SDS-PAGE (40mA for ~1.5h) and transferred onto a polyvinylidene di-
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fluoride membrane (Millipore, Bedford, MA) using a western transfer apparatus (Bio-
Rad Mini-Protean) with a transfer buffer (25mM Tris base, pH 8.3, 192mM glycine) 
for 1h at 100V. After blotting, membranes were blocked with 5% dry milk in TBS-
Tween (50mM Tris base, pH 7.5, 150mM NaCl, 0.1% Tween) for 30min at RT. After 
that, membranes were incubated with the first antibody solution (5% dry milk in 
TBS-Tween for unphosphorylated antibodies and 5% BSA in TBS-Tween for phos-
phorylated antibodies) overnight at 4°C.  The next day, membranes were washed 
with TBS-Tween and incubated with the respective secondary antibody (5% dry milk 
in TBS-Tween) for 1h at RT. After washings with TBS-Tween, detection of proteins 
was done using the chemiluminescence kit (Western Lightning®–ECL, Enhanced 
Chemiluminescence Substrate, PerkinElmer) and enhanced chemiluminescence 
films (HyperfilmTM ECL, Amersham/GE Healthcare). Ponceau red staining was per-
formed with each membrane to demonstrate equal protein loading of the samples. 
 
3.5.1 Primary Antibodies 
Name       Company 
4E-BP1      Cell Signaling 
Bax       Santa Cruz Biotechnologies 
Bcl-x       BD Biosciences 
Bid        R&D Systems  
Bim       Sigma 
c-jun       Cell Signaling 
Caspase-9      Cell Signaling 
CDK2       Santa Cruz Biotechnologies 
CDK4       NeoMarkers 
cIap1       Abcam  
cyclin A      Santa Cruz Biotechnologies 
cyclin B1      Santa Cruz Biotechnologies 
cyclin D1      BD Biosciences 
cyclin E      Santa Cruz Biotechnologies  
eIF-4A       Cell Signaling 
eIF-4E       Cell Signaling 
Fas       Santa Cruz Biotechnologies 
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Flip-s       Stressgen 
Mcl-1       Rockland 
phospho-Akt (Ser473)    Cell Signaling  
phospho-eIF-2α (Ser51)    Cell Signaling  
phospho-eIF-4G (Ser1108)    Cell Signaling  
phospho-S6 ribosomal protein (Ser240/244)  Cell Signaling 
phospho-Rb (Ser780)     Cell Signaling 
p21       BD Biosciences 
p27       Santa Cruz Biotechnologies 
p53       R&D Systems 
 
3.5.2 Secondary Antibodies 
Name       Company 
Goat anti-mouse IgG-HRP    Santa Cruz Biotechnologies 
Goat anti-rabbit IgG-HRP    Santa Cruz Biotechnologies 
Donkey anti-goat IgG-HRP    Santa Cruz Biotechnologies 
 
3.6 Immunoprecipitation (IP) 
Frozen liver tissue was grinded in liquid nitrogen, resuspended in RIPA buffer (1% 
NP40, 0,5% DOC, 0,1% SDS, 50mN Tris pH 8.0, 80mM NaCl, 50mM NaF, 1mM 
EDTA, 1mM EGTA, 20mM Na4P2O7; Inhibitors: 0,1µM Vanadate, 2,5ng/ml Leu-
peptin, 0,15nM Benzamidine, 12,5ng/ml Pepstatin, 2,5mM PMSF) followed by soni-
cation (20sec at amplification 4, cycle 1).  Five-hundred micrograms of protein were 
pre-cleaned and incubated with 1µg of antibody for 2h at 4°C. Protein complexes 
were precipitated using protein A-sepharose beads for 1h at 4°C and subjected to 
Western Blotting using the indicated antibodies. 
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3.7 Partial hepatectomy 
C57BL/6 mice were operated on under sterile conditions between 8:00 and 11:00 
A.M. (Mitchell and Willenbring, 2008). Shortly thereafter, the animals were narco-
tized with a 10% ketamine/0.04% xylazine solution (12.5µl/g mouse). The abdomen 
cavity was longitudinally incised just below to the rib cage. The left lateral and me-
dian lobes were individually ligated and removed. Then the abdomen was closed by 
suturing the inner and outer skin separately. The animals recovered on a 37°C heat-
ing pad. The mortality of the animals following PH was <1%.  Mice were treated ei-
ther with RAD001 (10mg/kg/d) or a placebo 24 hours before and after partial 
hepatectomy. Two hours prior to harvest, the animals were injected with bromode-
oxyuridine (BrdU, 100mg/kg) by intraperitoneal injection. For each time point stud-
ied, 3 animals were harvested.  
 
3.8 Hepatocyte isolation and transplantation 
Mouse liver was perfused using three different solutions (solution 1: EBSS without 
Ca and Mg with 0.5mM EGTA; solution 2: EBSS with Ca and Mg containing 10mM 
HEPES pH 7.4; solution 3: EBSS with Ca and Mg containing 10mM HEPES pH 7.4, 
0.04mg/ml trypsin inhibitor, and 0.05mg/ml liberase blendzyme 3). After that, the 
liver was disrupted in FCS to stop collagenase activity by tearing and pipetting. 
Cells were filtered through a 100µM nylon mesh into a sterile falcon tube containing 
10ml of media. Hepatocytes were pelled by centrifugation for 2min at 300rpm.  
Then wild-type hepatocytes were transplanted into Fah/p21-/- mice. One and one-
half million cells were injected into the spleen. The animals were treated with 
10mg/kg/d RAD001 or a placebo for 3 months after NTBC withdrawal and treated 
with BrdU containing 0.8mg/ml in drinking water for 3 days before harvesting. Five 
mice per group were harvested. 
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3.9 mAb Fas injection and caspase-3 activity 
Fah-deficient mice (n=4) were treated with RAD001 for 14 days after NTBC with-
drawal. At the end of the treatment, mice were injected intraperitoneally with a 
monoclonal anti-Fas antibody (Jo-2, purified anti-mouse CD95 (Fas); Becton Dick-
inson GmbH) at a dosage of 0.5µg/g mouse. The animals were harvested after 4h. 
Liver lysates were prepared by homogenization in hypotonic buffer (40mmol 
HEPES, 20% Glycerol, 4mmol DTT, pH 7.4).  Lysates were centrifuged at 
13,200rpm for 10min, and extracted proteins (50µg) were tested in triplicate ex-
periments by measuring the proteolytic cleavage of a specific fluorogenic substrate 
for caspase-3 (Ac-DEVC-AMD, Caspase-3 (CPP32) Fluorogenic Substrate, Becton 
Dickinson GmbH). Samples treated with caspase-3 activity inhibitor (Ac-DEVD-
CHO, Caspase-3 (CCP32) Inhibitor; Becton Dickinson GmbH) were used as refer-
ence. 
 
3.10  Histology 
3.10.1  Hematoxylin and Eosin (H&E) staining 
Five micrometer sections were deparaffinazed in xylene and rehydrated in 3 differ-
ent concentrations of ethanol solutions. After washing with distilled water, nuclei 
were stained with hematoxylin solution (Merck) for 15-30sec. Sections were washed 
with warm tap water to allow the stain to develop. After rinsing with distilled water, 
cytoplasms were stained with acidified eosin solution (Sigma-Aldrich) for 2min. Sec-
tions were rehydrated, cleared and mounted with a xylene-based mounting medium. 
 
3.10.2  TdT-mediated dUTP-biotin nick end labeling (TUNEL) assay 
Detection of DNA strand breaks in apoptotic cells was performed with an in situ cell 
death detection kit (Roche). Five micrometer sections were deparaffinazed and re-
hydrated. After washing with distilled water, endogenous peroxidases were blocked 
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with 3% H2O2 for 10min. Antigens were unmasked by cooking sections in a micro-
wave for 15min using citric acid retrieval buffer (10mM Tris Base, 0.05% Tween). 
Tissue permeabilization was done by incubating sections in a 20µg/ml proteinase K 
solution. Then, sections were fixed with 4% paraformaldehyde for 1h. After a sec-
ond permeabilization with 0.1% Triton/0.1% sodium citrate, TUNEL analysis was 
performed by a fluorescein detection system, using reagents from a Roche kit. Sec-
tions were mounted with a DAPI-containing medium.  Positive hepatocytes from 10 
non-overlapping x200 fields per slide were counted. 
 
3.10.3  5-bromo2'-deoxy-uridine (BrdU) staining 
DNA synthesis was measured by BrdU incorporation into DNA strands. Shortly 
thereafter, 5µm sections were deparaffinized and rehydrated. After washing with 
distilled water, antigen unmasking was performed by incubating sections in citric 
acid retrieval buffer (10mM Tris Base, 0.05% Tween) in a water bath at 95°C for 
35min. After cooling down and washing with distiller water, DNA denaturation was 
performed in 2N HCl solution for 1h. Endogenous peroxidases were blocked with 
3% H2O2 for 15min. To avoid non-specific binding of the antibody, sections were 
blocked with 10% normal goat serum for 30min. Then, sections were incubated with 
anti-BrdU antibody (1:200, 5% normal goat serum, GE Healthcare) overnight at 
4°C. The next day, biotynilated goat anti-mouse IgG  antibody (1:200, 5% normal 
goat serum, Invitrogen) was dropped into sections and incubated for 30min at RT. 
After washing, sections were incubated with HRP-Streptavidin Plus (Vector labora-
tories) for 30min at RT. Then, detection was done by adding AEC solution (Vector 
laboratories) until desired stain intensity developed. Sections were counterstained 
with hematoxylin and mounted with a water-based mounting media (Vector labora-
tories).  Positive hepatocytes from 10 non-overlapping x200 fields per slide were 
counted. 
 
3.10.4  Ki67 staining 
Hepatocyte proliferation was checked by the presence of Ki67 cell cycle-related nu-
clear protein expressed in all phases of the active cell cycle.  Shortly thereafter, 
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5µm sections were deparaffinized and rehydrated. After washing with distilled water, 
antigen unmasking was performed by incubating sections in EDTA retrieval buffer 
(1mM EDTA, 10mM Tris Base, 0.05% Tween) in a water bath at 95°C for 35min. 
After cooling down and washing with distiller water, endogenous peroxidases were 
blocked with 3% H2O2 for 10min. Endogenous avidin/biotin were blocked with 
Avidin/Biotin solutions (Avidin/Biotin Blocking Kit, Vector laboratories) for 15min 
each at RT. To reduce unspecific binding of antibodies, sections were blocked with 
5% normal goat serum for 1h at RT. Then, sections were incubated with anti-Ki67 
antibody (1:500, 2% normal goat serum, Vector laboratories) overnight at 4°C. The 
next day, sections were incubated with broad-spectrum plus antibody (Vector labo-
ratories) for 30min at RT. After washing, sections were incubated with HRP-
Streptavidin Plus (Vector laboratories) for 30min at RT. Then, detection was done 
by adding AEC solution (Vector laboratories) until the desired stain intensity devel-
oped. Sections were counterstained with hematoxylin and mounted with a water-
based mounting media (Vector laboratories). 
 
3.10.5  Oval cell (A6) staining 
Five micrometer sections were deparaffinazed and rehydrated. After washing with 
distiller water, endogenous peroxidases were blocked with 0.001M periodic acid and 
0.1M sodium borohydride, both for 10 min at RT. Sections were incubated with anti-
A6 antibody (1:100, provided by V. Factor (NIH, Washington DC)) overnight at 4°C.  
The next day, Alexa Fluor anti-rat antibody (1:100, Invitrogen) was applied to sec-
tions for 30min at RT. Finally, sections were mounted with a DAPI-containing me-
dium. 
 
3.10.6  p21 staining 
Five micrometer sections were deparaffinazed and rehydrated. After washings with 
distilled water, the antigen unmasking was done by cooking the slides in a water 
bath with citrate retrieval buffer (10mM citrate acid, 0.05% Tween) for 35min at 
96°C. After cooling down and washings, avidin/bioti ns were blocked using 
Avidin/Biotin solutions (Avidin/Biotin Blocking Kit, Vector laboratories) for 5min each 
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at RT. To prevent unspecific binding of antibody, sections were blocked with 5% 
normal horse serum for 30min at RT. Then, anti-p21 antibody (1:50, 2% normal 
horse serum, Santa Cruz Biotechnologies) was added to the sections and incubated 
overnight at 4°C. The next day, endogenous peroxida ses were blocked with 3% 
H2O2 for 10min at RT. Slides were incubated with biotynilated anti-goat antibody 
(ready-to-use antibody, Vector laboratories) for 30min at RT. Then, detection was 
done by adding AEC solution (Vector laboratories) until the desired stain intensity 
developed. Sections were counterstained with hematoxylin and mounted with a wa-
ter-based mounting media (Vector laboratories). 
 
3.10.7  Co-staining of Fah with BrdU 
Five micrometer sections were deparaffinazed and rehydrated. After washings with 
distilled water, an antigen unmasking was done by cooking the slides in a water 
bath with citrate retrieval buffer (10mM citrate acid, 0.05% Tween) for 35min at 
96°C. After cooling down and washings, DNA was dena turated by incubating slides 
in 2N HCl for 1h at RT. To reduce unspecific binding of antibodies, blocking was 
made by incubating slides with 5% normal goat serum for 15min at RT.  Then, anti-
BrdU antibody (1:200, 1% BSA, GE Healthcare) was applied to the slides and incu-
bated overnight at 4°C. The next day, the slides we re incubated with Cy3 anti-
mouse antibody (1:400, 1% BSA, Invitrogen) for 30min at RT. Anti-Fah antibody 
(1:1000, 1%BSA, provided by R. Tanguay) was added to the slides and incubated 
for 1h at RT. After that, the slides were incubated with Alexa Fluor 488 goat anti-
rabbit antibody (1:1000, 1% BSA, Invitrogen) for 30min at RT. Finally, the slides 
were mounted with a DAPI-containing mounting medium. 
 
3.10.8  Senescence-associated ß-Gal staining 
Seven micrometer frozen sections were fixed in 0.2% glutaraldehyde for 3min. After 
washing with PBS, sections were incubated in freshly prepared senescence-
associated ß-gal staining solution (1mg/ml of 5-bromo-4-chloro-3-indolyl ß-D galac-
toside (X-gal) in DMF, 40mM citric acid, sodium phosphate (pH 6.0), 5mM potas-
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sium ferrocyanide, 5mM potassium ferricyanide, 150mM NaCl, 2mM MgCl2) for 16-
17h at 37°C. Sections were washed in PBS and counte rstained with eosin. 
 
3.11  Microarray 
Total RNAs from livers were extracted from 3 mice in each group using the Qiagen 
RNAeasy kit. The isolated RNAs were applied to murine Affymetrix GeneChip MOE 
430 2.0 GeneChip arrays (Affymetrix, Santa Clara, LA, USA) in the Microarray Core 
Facility of the Helmholtz Centre for Infection Research. Data analysis was per-
formed using the Affymetrix Expression Analysis software GCOS 1.4.  
 
3.12  Statistical analysis 
Data are expressed as mean ± SD determined by one-way analysis of variance fol-
lowed by Student T test to determine significance. 
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4 Results 
4.1 RAD001 prevents proliferation of hepatocytes with DNA 
damage 
Fah-deficient mice, that were taken off NTBC, mimic the liver failure and pathology 
of the human disease HT1 (Grompe et al., 1993).  In order to analyze the role of 
mTOR in liver injury induced by FAA accumulation, Fah-deficient mice were taken 
off NTBC for 15 days and treated with either RAD001 or placebo. This time point 
was chosen because when mice are off NTBC for 15 days, they still have the same 
weight and overall health as mice on NTBC despite hepatic dysfunction.  
 
First, the inhibition of mTOR activity by RAD001 treatment was verified. Phosphory-
lation of two major mTOR downstream targets, S6 and 4E-BP1, was analyzed by 
Western Blotting. Phosphorylation of S6 was evident in placebo-treated Fah-/- mice 
that were on and off NTBC. After RAD001 treatment, phosphorylation of S6 was 
markedly suppressed in those livers (figure 9).  4E-BP1 has at least five phosphory-
lation states, and the various phosphorylated forms of the protein are resolved into 
three bands by SDS-PAGE; those forms have been identified as α (least phos-
phorylated and fastest migrating), ß (intermediate) and γ (most phosphorylated and 
slowest migrating) (Yang et al., 2009).  Placebo-treated Fah-deficient mice that 
were taken off NTBC, showed hyperphosphorylation of 4E-BP1; however, after 
RAD001 treatment, a slight reduction of 4E-BP1 phosphorylation was detected (fig-
ure 9). 
 
Activation of Akt was analysed by Western Blotting. In placebo-treated Fah-/- mice, 
no activation of this kinase was observed.  Suppression of mTORC1 activates Akt 
kinase in some cells due to a negative feedback loop between S6 kinase and insulin 
receptor substrate-1 (IRS1) (Guertin and Sabatini, 2007).  However, no activation of 
Akt was seen in Fah-deficient mice on and off NTBC after RAD001 treatment (figure 
9).   
 
Results 
 54  
 
Figure 9  RAD001 significantly reduced the levels of S6 phosphorylation 
in Fah-deficient mice 
RAD001 or placebo was administered to Fah-/- mice for 14 days after NTBC 
withdrawal (n=4).  Phosphorylation of mTOR downstream targets S6 and 4E-
BP1 were analyzed by Western Blotting. Positive control for phospho-Akt: To-
tal liver lysate from insulin injected mice. 
 
 
The mTOR pathway is involved in the initiation of cap-dependent translation.  
Therefore, the expression of eIF-4F components was also analyzed in Fah-deficient 
mice.  In Fah-/- mice that were on NTBC, the expression of eIF-4E and eIF-4A was 
not altered by RAD001 treatment; contrary, no phosphorylation of eIF-4G and eIF-
2α was detected in those mice.  After NTBC withdrawal, induction of eIF-4E and 
phosphorylation of eIF-4G and eIF-2α was seen in Fah-/- mice; however,  RAD001 
treatment did not alter the expression of eIF-4E and eIF-4A, whereas eIF-4G and 
eIF-2α phosphorylation was moderately reduced (figure 10), indicating that the ex-
pression of translation initiation factors was not significantly affected by RAD001 
treatment in Fah-/- mice. 
 
 
Figure 10  RAD001 treatment did not significantly affect the expression 
of translation initiation factors 
RAD001 or placebo was administered to Fah-/- mice for 14 days after NTBC 
withdrawal (n=4).  Immunoblots showing the expression of several transla-
tion initiation factors.  
 
 
In addition, the effect of RAD001 in tyrosine aminotransferase (TAT), 4-
hydroxyphenylpyruvate dioxygenase (HPD), homogentisic acid oxidase (HGD) and 
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maleylacetoacetate isomerise (MAAI), enzymes involved in the tyrosine catabolism 
pathway, was analyzed by microarrays.  Previously, it was shown that accumulation 
of FAA leads to a negative feedback regulation of enzymes upstream in the tyrosine 
catabolism pathway (Langlois et al., 2006).  However, a similar down regulation of 
all genes was evident in RAD001 and placebo-treated Fah-/- mice that were taken 
off NTBC, indicating that the RNA expression of those genes was not affected by 
the inhibition of mTOR; and thereby RAD001 treatment did not induce accumulation 
of the toxic intermediates in those mice (figure 11). 
 
 
Figure 11  Expression levels of enzymes in the tyrosine catabolism 
pathway 
mRNA levels of several enzymes involved in the tyrosine metabolism were 
measured by microarray analysis in mice that were on and off NTBC. Open 
bars: Fah-/- 100% NTBC placebo/Fah-/- 0% NTBC placebo, close bars: Fah-/- 
100% NTBC RAD001/Fah-/- 0% NTBC RAD001. 
 
 
The p53/p21 pathway is strongly activated in Fah-/- mice after NTBC withdrawal due 
to severe DNA damage induced by FAA (Willenbring et al., 2008a).  Therefore, in 
this study the expression of several proteins involved in the pathway was analyzed 
by Western Blotting.  Contrary to p27, no expression of p53 and p21 was detected 
in Fah-/- mice that were on NTBC (figure 12).  As expected, up-regulation of p53 and 
p21 was observed in Fah-/- mice after NTBC withdrawal.  Interestingly, the levels of 
those proteins were markedly reduced after RAD001 treatment and NTBC with-
drawal (figure 12).  Levels of p27 were slightly induced in Fah-/- mice that were 
taken off NTBC; however, RAD001 treatment did not affect them.  These data sug-
gest that RAD001 treatment blocks p53/p21 pathway in Fah-/- mice that were taken 
off NTBC. 
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Figure 12  RAD001 significantly suppressed the p53/p21 pathway 
RAD001 or placebo was administered to Fah-/- mice for 14 days after NTBC 
withdrawal (n=4).  Immunoblots revealed reduced p53 and p21 protein levels 
in RAD001-treated Fah-/- mice that were off NTBC. 
 
 
Histologies from Fah-/- mice that were on NTBC revealed no apparent pathology, 
whereas small foci of necroinflammation and some hepatocytes with multinucleation 
were evident in mice that were taken off NTBC (figure 13A).  Treatment with 
RAD001 did not affect overall liver injury in livers from mice that were on and off 
NTBC (figure 13A). 
 
It has been shown that proliferation is markedly reduced in Fah-deficient hepato-
cytes due to induction of p21 (Willenbring et al., 2008a). Here, hepatocyte prolifera-
tion was determined by BrdU incorporation.  Several BrdU-positive hepatocytes 
were seen in both RAD001 and placebo-treated Fah-/- mice that were on NTBC, in-
dicating that RAD001 treatment did not affect baseline proliferation of healthy hepa-
tocytes (figure 13A,B). As expected, no BrdU-positive cells were found in Fah-/- mice 
that were off NTBC due to up-regulation of p21 (figure 13A).  Interestingly, prolifera-
tion of hepatocytes was almost suppressed in RAD001-treated Fah-/- mice that were 
taken off NTBC despite the loss of p21 (figure 13A,B). Moreover, senescence was 
analyzed by SA-ß-Gal staining. No significant differences were found between 
RAD001 and placebo-treated Fah-/- mice that were on and off NTBC (figure 13A). 
Taking these together, the data suggest that treatment with RAD001 prevents the 
proliferation of hepatocytes with DNA damage despite the loss of p21. 
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Figure 13  RAD001 significantly reduced the accumulation of p21 and 
suppressed proliferation of hepatocytes with DNA damage in Fah-/- 
mice taken off NTBC  
RAD001 or placebo was administered to Fah-/- mice for 14 days after NTBC 
withdrawal (n=4).  A Representative H&E, p21, BrdU and SA-ß-Gal stainings 
of liver sections are shown (original magnification x200). B BrdU positive 
cells were counted at x200 magnification. Average ± SD is shown 
(*p≤0.0001, closed bars: on NTBC; open bars: off NTBC; Pla.:Placebo, 
RAD: RAD001).  
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4.2 RAD001-induced cell cycle arrest does not depend on 
p21 
The data shown above suggest that the cell-cycle arrest induced by RAD001 treat-
ment does not require p21. In order to confirm this observation, the drug was addi-
tionally tested in Fah/p21-/- mice that were on and off NTBC for 15 days.  
 
Similar to the observation in Fah-/- mice, phosphorylation of S6 and 4E-BP1 was 
seen in placebo-treated Fah/p21-/- mice that were on and off NTBC (figure 14); 
however, RAD001 treatment blocked the phosphorylation of S6 and caused a slight 
shift of 4E-BP1 to the hypophosphorylated form in mice after NTBC withdrawal.  Akt 
levels were not detectable in those mice (figure 14). 
 
 
Figure 14  RAD001 reduces the phosphorylation levels of S6 in 
Fah/p21-/- mice taken off NTBC 
RAD001 or placebo was given to Fah/p21-/- mice for 14 days after NTBC 
withdrawal (n=4).  Immunoblots from total liver extract are shown. Phos-
phorylation of S6 and 4E-BP1 was reduced in RAD001-treated mice. Posi-
tive control for phospho-Akt: Total liver lysate from insulin-injected mice. 
 
 
Expression of several translation initiation factors was analyzed by Western Blot-
ting.  In Fah/p21-/- mice that were on NTBC, eIF-4E and eIF-4A levels were not af-
fected by RAD001 treatment.  Contrary, no phosphorylation of eIF-4G and eIF-2α 
was seen in those mice (figure 15).  After NTBC withdrawal, levels of eIF-4E and 
phosphorylation of eIF-4G and eIF-2α were increased (figure 15).  However, 
RAD001 treatment significantly reduced the expression of those proteins.  Levels of 
eIF-4A were not altered (figure 15).  Similar to Fah-/- mice, RAD001 did not signifi-
cantly affect the expression of translation initiation factors in Fah/p21-/- mice. 
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Figure 15  Expression of eIF-4F components in Fah/p21-/- mice 
RAD001 or placebo was given to Fah/p21-/- mice for 14 days after NTBC 
withdrawal (n=4).  Expression of several translation initiation factors was 
analyzed by Western Blotting. 
 
 
Additionally, activation of p53/p21 pathway was also analysed.  In Fah/p21-/- mice 
that were on NTBC, p27 expression levels were not changed after RAD001 treat-
ment (figure 16).  After NTBC withdrawal, the levels of p53 expression were in-
creased in placebo-treated Fah/p21-/- mice; however, they were significantly re-
duced in RAD001-treated mice (figure 16).  Moreover, p27 levels were slightly re-
duced in mice that were taken off NTBC after RAD001 treatment when compared 
with placebo-treated mice (figure 16).  Immunoblot of p21 confirmed the absence of 
the protein in those mice.  These data suggest that RAD001 treatment reduces the 
p53 expression in Fah/p21-/- mice that were taken off NTBC. 
 
 
Figure 16 Protein levels of p53 were reduced in RAD001 Fah/p21-/--
treated mice 
RAD001 or placebo was given to Fah/p21-/- mice for 14 days after NTBC 
withdrawal (n=4).  Immunoblots showing the expression of p53, p21 and 
p27. 
 
 
Liver histology did not reveal significant differences between RAD001 and placebo 
Fah/p21-/--treated mice (figure 17A).  Moreover, proliferation of hepatocytes was de-
termined by BrdU incorporation.  Similar to the observation in Fah-/- mice, treatment 
with RAD001 did not affect proliferation of healthy hepatocytes; a similar amount of 
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BrdU positive hepatocytes was seen in both RAD001 and placebo-treated Fah/p21-/- 
mice that were on NTBC (figure 17A,B).  In Fah/p21-/- livers from mice that were 
taken off NTBC, BrdU staining showed a high number of positive hepatocytes.  In 
contrast, however, few BrdU positive cells were found in RAD001-treated Fah/p21-/- 
mice that were off NTBC (figure 17A,B).  SA-ß-Gal staining showed no significant 
differences between RAD001 and placebo-treated Fah/p21-/- mice that were on and 
off NTBC (figure 17A).  Altogether, the data presented above suggest that the cell-
cycle arrest that was induced in liver by RAD001 treatment is clearly independent of 
p21. 
 
 
Figure 17  The ability of RAD001 to impair proliferation of hepatocytes 
is clearly independent on p21 
RAD001 or placebo was given to Fah/p21-/- mice for 14 days after NTBC 
withdrawal (n=4). A Representative H&E, BrdU and SA-ß-Gal immunohis-
tostainings. B BrdU positive hepatocytes were counted in x200 magnification 
and results are represented as mean ± SD (*p≤0.0001, closed bars: on 
NTBC; open bars: off NTBC, Pla.:Placebo, RAD: RAD001).  
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4.3 RAD001-induced cell-cycle arrest is attenuated in ab-
sence of p53 
In order to determine whether the cell-cycle arrest induced by RAD001 treatment 
requires p53, the effect of the drug was examined in Fah/p53-/- mice, in which p53 
was specifically deleted in hepatocytes. Mice that were on and off NTBC were 
treated with either RAD001 or placebo for 15 days.  In Fah/p53-/- mice that were on 
NTBC, RAD001 treatment did not affect the expression of 4E-BP1; phosphorylation 
of S6 and Akt was not detected in those mice (figure 18).  Similar to the observa-
tions seen in Fah-/- and Fah/p21-/- mice, Fah/p53-/- mice that were taken off NTBC 
showed phosphorylation of S6 and 4E-BP1 and no expression of Akt.  RAD001 
treatment blocked the phosphorylation of S6 and did not affect phosphorylation of 
Akt.  In contrast to Fah-/- and Fah/p21-/- mice, treatment with RAD001 did not modify 
the phosphorylation of 4E-BP1 in Fah/p53-/- mice (figure 18). 
 
 
Figure 18  4E-BP1 and phosphorylation of S6 and Akt in Fah/p53-/- mice 
RAD001 or placebo was administered to Fah/p53-/- mice for 14 days after 
NTBC withdrawal (n=4).  Immunoblots showing the levels of designed pro-
teins in livers. Positive control for phospho-Akt: Total liver lysate from insulin-
injected mice. 
 
 
Treatment with RAD001 did not affect the protein expression of eIF-4E and eIF-4A 
in Fah/p53-/- mice that were on NTBC; phosphorylation of eIF-4G and eIF-2α was 
not detected in those mice (figure 19).  However, phosphorylation of eIF-4G and 
eIF-2α was increased in placebo-treated Fah/p53-/- mice that were taken off NTBC.  
Moreover, phosphorylation levels of eIF-4G were reduced after RAD001 treatment; 
interestingly, no changes in phosphorylation of eIF-2α were detected.  No significant 
differences in eIF-4E and eIF-4A levels were seen in Fah/p53-/- mice that were 
taken off NTBC (figure 19).   
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Figure 19  Expression of eIF-4F components in Fah/p53-/- mice 
RAD001 or placebo was administered to Fah/p53-/- mice for 14 days after 
NTBC withdrawal (n=4).  Immunoblots showing the levels of designed pro-
teins in livers. 
 
Furthermore, activation of p53/p21 pathway was analyzed.  Low levels of p27 were 
detected in Fah/p53-/- mice that were on NTBC.  After NTBC withdrawal, signifi-
cantly low levels of p21 were detectable in placebo-treated Fah/p53-/- mice, which 
were reduced by treatment with RAD001 (figure 20). No significant changes in p27 
levels in RAD001 and placebo-treated Fah/p53-/- mice that were taken off NTBC 
were seen (figure 20).  Immunoblot of p53 confirmed the absence of the protein in 
those mice. 
 
 
Figure 20  p21 expression is reduced after RAD001 treatment in 
Fah/p53-/- mice that were taken off NTBC 
Immunoblots showing the protein levels of p53, p21 and p27. Control for 
p21: total liver lysate from Fah-/-  that were off NTBC mice. 
 
 
Histology did not reveal significant differences between RAD001 and placebo-
treated livers of Fah/p53-/- mice.  Hepatocyte proliferation was determined by BrdU 
incorporation.  Similar to the observations in Fah-/- and Fah/p21-/-, treatment with 
RAD001 did not affect proliferation of healthy hepatocytes (figure 21A,B).  Addition-
ally, placebo-treated Fah/p53-/- mice that were taken off NTBC displayed BrdU-
positive hepatocytes despite activation of p21 (figure 21A).  Interestingly, however, 
BrdU-positive hepatocytes were still detectable after RAD001 treatment, although 
there was complete blocking of p21 expression (figure 21A).  Treatment with 
RAD001 did not completely suppress the proliferation of hepatocytes in Fah/p53-/- 
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mice that were taken off NTBC (figure 21A,B).  Additionally, no significant differ-
ences were seen in SA-ß-Gal staining after RAD001 treatment (figure 21A).  Alto-
gether, these data suggest that the ability of RAD001 to impair the cell cycle is in-
dependent of p21 but requires an intact p53 pathway. 
 
 
Figure 21  Loss of p53 significantly attenuated the anti-proliferative ef-
fects of RAD001  
RAD001 or placebo was administered to Fah/p53-/- mice for 14 days after 
NTBC withdrawal. A Representative H&E, p21, BrdU and SA-ß-Gal immu-
nohistostainings. B BrdU-positive hepatocytes were counted in x200 magni-
fication and results are represented as mean ± SD (*p≤0.0001, closed bars: 
on NTBC; open bars: off NTBC, Pla.:Placebo, RAD: RAD001).  
 
 
Results 
 64  
4.4 RAD001 delays proliferation of healthy hepatocytes fol-
lowing partial hepatectomy 
The data above revealed that RAD001 treatment specifically inhibits proliferation of 
damaged hepatocytes. Surprisingly, however, treatment with RAD001 did not affect 
baseline proliferation of healthy hepatocytes: a similar number of BrdU-positive cells 
was detectable in RAD001 and placebo-treated Fah-/-, Fah/p21-/- and Fah/p53-/- mice 
that were on NTBC, suggesting that RAD001 is not, or at least less, effective in 
healthy cells.  Therefore, to analyze the effect of RAD001 on healthy hepatocytes, 
C57BL/6 mice were treated either with RAD001 or placebo before and after 2/3 par-
tial hepatectomy.  Livers were collected at different time points. 
 
Liver regeneration following 2/3 partial hepatectomy offers a unique in vivo system 
to study gene regulation and cell-cycle processes in adults, differentiated, non-
transformed cells.  After resection of the left lateral and median lobes of the liver, 
the remaining hepatocytes and non-parenchymal cells synchronously exit their rest-
ing G0 state.  Entrance into G1 and the cell cycle is marked by a similar pattern of 
cyclin and CDK genes induction and expression.  Peaks in DNA synthesis for mice 
occur around 36h after partial hepatectomy.  Mitosis proceeds 6-8h after DNA syn-
thesis. The re-growth of the liver following partial hepatectomy represents compen-
satory hyperplasia of the remaining cells and does not involve de-differentiation of 
the remaining cells. Within 4 days, the liver cell number is almost completely re-
turned to normal, and within 7-10 days the extracellular matrix, micro-architecture 
and liver mass are restored.  Many of the cyclins demonstrate dramatic patterns of 
cell cycle-related expression at the transcript level following partial hepatectomy in 
mice. Cyclins D exhibits induced transcript abundances that fluctuate and peak co-
incident with the G1 phase of the cell cycle. 
 
In this study, phosphorylation levels of S6 and 4E-BP1 were determined.  After 6 
hours of partial hepatectomy, phosphorylation levels of S6 were increased, which 
were clearly reduced by RAD001 treatment (figure 22).  In contrast, levels of 4E-
BP1 were similar for RAD001 and placebo-treated C57BL/6 mice following partial 
hepatectomy.  No phosphorylation of Akt was seen in those mice (figure 22). 
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Figure 22  Levels of 4E-BP1 and phosphorylation of S6 and Akt in 
C57BL/6 mice RAD001 and placebo-treated after partial hepatectomy 
Partial hepatectomy was performed as described in Materials and Methods. 
RAD001 or placebo was administrated to mice two days before surgery until 
harvesting.  Immunoblots showing the levels of designed proteins in livers. 
Positive control for phospho-Akt: Total liver lysate from insulin-injected mice. 
 
Moreover, the expression of eIF-4F components was determined.  Protein levels of 
eIF-4E and eIF-4A were not altered after partial hepatectomy, and treatment with 
RAD001 did not affect them. Induction of eIF-4G protein was detected in placebo-
treated mice after 6h of partial hepatectomy, which was markedly delayed up to 60h 
by RAD001 treatment.  Similarly, increased phosphorylation of eIF-2α was detected 
in placebo-treated mice after 6h and 10h of partial hepatectomy, which was clearly 
delayed in RAD001-treated mice (figure 23).  Additionally, no activation of Akt was 
detected in RAD001 and placebo-treated C57BL/6 mice after partial hepatectomy 
(figure 23). 
 
 
Figure 23  Expression of eIF-4F components in RAD001 and placebo-
treated C57BL/6 mice after partial hepatectomy 
Partial hepatectomy was performed as described in Materials and Methods. 
RAD001 or placebo was administrated to mice two days before surgery until 
harvesting.  Immunoblots showing levels of designed proteins in livers. 
 
 
Histology did not reveal significant differences between RAD001 and placebo-
treated mice after partial hepatectomy (figure 24).  Furthermore, hepatocyte prolif-
eration was analysed by BrdU incorporation.  Placebo-treated C57BL/6 mice dis-
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played multiple BrdU-positive cells 36h after partial hepatectomy, which occurred at 
the peak of DNA synthesis.  In contrast, no BrdU-positive cells were detectable in 
RAD001-treated mice 36h after partial hepatectomy.  Interestingly, however, multi-
ple BrdU-positive cells appeared 72h after partial hepatectomy in RAD001-treated 
mice, suggesting that treatment with RAD001 did not prevent but delayed entry for 
about the 36h into S-phase on cell cycle (figure 24). 
 
 
Figure 24  RAD001 only delay proliferation of healthy hepatocytes after 
partial hepatectomy 
Partial hepatectomy was performed as described in Materials and Methods. 
RAD001 or placebo was administered to mice two days before surgery until 
harvesting. Histological sections of paraffin-embedded livers are shown. 
Proliferating cells were detected by BrdU staining. Treatment with RAD001 
significantly delayed entry into the S-phase of C57BL/6 hepatocytes after 
PH.  
 
 
4.5 RAD001 affects global protein translation and expres-
sion of several cell cycle-related proteins 
Previous studies have shown that rapamycin and its analogues inhibit protein trans-
lation (Fingar and Blenis, 2004; Tang et al., 2001).  In order to analyze the effect of 
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RAD001 on overall protein translation, nutrient-induced growth after a period of fast-
ing was determined.  Fasting triggers a 40-50% reduction in liver weight, total pro-
tein and ribosome content (Volarevic et al., 2000).  To determine weather RAD001 
inhibits hepatocyte proliferation by affecting protein translation, C57BL/6 mice 
treated either with RAD001 or placebo were deprived of food for 48h before re-
feeding for 24h.   
First, overall protein content was determined in both groups; however, no significant 
differences were found (figure 25). Next, to specifically analyze the effect of 
RAD001 on protein synthesis, RAD001 was given at the beginning of the re-feeding 
phase to the C57BL/6 mice.  In this second approach, treatment with RAD001 sig-
nificantly suppressed overall protein content (figure 25).   
 
 
Figure 25  RAD001 affects the protein content in liver  
C57BL/6 mice were fasted for 48h and re-fed for 24h. RAD001 or placebo 
was administered during both the fasting and re-feeding period.  Protein 
content was determined in livers of RAD001 and placebo-treated mice 
(*p≤0.0001, C: control group; Pla.: Placebo; RAD: RAD001; RAD*: RAD001 
treatment only during re-feeding phase). 
 
 
Interestingly, phosphorylation levels of 4E-BP1 and Akt plus the expression of eIF-
4E were not altered during starvation and re-feeding with RAD001 treatment.  
Phosphorylation of S6 was inhibited only in RAD001-treated mice during re-feeding 
period (figure 26).  Together, these data show that inhibition of mTOR by RAD001 
significantly inhibits overall protein synthesis in hepatocytes. 
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Figure 26  Immunoblots showing protein expression of 4E-BP1 and 
eIF-4E and phosphorylation of S6 and Akt in fasted and refed livers 
Positive control for phospho-Akt: Total liver lysate from insulin-injected mice. 
 
To understand better how RAD001 inhibits proliferation of hepatocytes, the expres-
sion of cell cycle-regulating proteins was analyzed in Fah-deficient mice that were 
on and off NTBC and in C57BL/6 mice following partial hepatectomy.  In Fah-/- mice 
that were on NTBC, levels of cyclin E and B remain unchanged after RAD001 and 
placebo treatment (figure 27).  No expression of phospho-Rb, cyclin D1 and A, and 
c-jun was detected in those mice.  However, after NTBC withdrawal, an increase in 
those proteins was seen in placebo treated-mice (figure 27).  Interestingly, RAD001 
treatment reduced the phosphorylation of Rb and the expression of cyclin D1 and c-
jun. No changes of levels of cyclin E and B were seen in mice that were taken off 
NTBC (figure 27). 
 
 
Figure 27  Expression levels of several cell cycle related protein in Fah-
/-mice 
RAD001 or placebo was administered to Fah -/- mice for 14 days after NTBC 
withdrawal.  Immunoblots showing the expression of designed proteins. 
 
 
In Fah/p21-/- mice that were on NTBC, the expression of cyclin D1, E and B was de-
tected in placebo-treated mice, and no significant changes were seen after RAD001 
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treatment (figure 28).  No phosphorylation of Rb and expression cyclin A and c-jun 
was observed in those mice.  After NTBC withdrawal, however, the expression was 
increased in most of the protein analyzed with the exception of cyclin A.  Similar to 
the Fah-/- mice, RAD001 treatment suppressed the phosphorylation of Rb and the 
expression of cyclin D and c-jun (figure 28).  No significant changes in levels of cy-
clin E and B were seen in mice that were taken off NTBC. 
 
 
Figure 28  Levels of several cell-cycle related proteins in Fah/p21-/ mice 
RAD001 or placebo was administered to Fah/p21 -/- mice for 14 days after 
NTBC withdrawal.  Immunoblots showing the expression of designed pro-
teins.  Positive control for cyclin A: Total liver lysate from C57BL/6 mice after 
48h partial hepatectomy. 
 
 
 
In Fah/p53-/- mice that were on NTBC, the expression of phospho-Rb, cyclin E and 
B was detected in placebo-treated mice; after RAD001 treatment, levels of phos-
pho-Rb and cyclin E were slightly reduced (figure 29).  Interestingly, all proteins 
analyzed were significantly induced after NTBC withdrawal.  RAD001 treatment no-
tably reduced the phosphorylation of Rb, cyclin D1 and A.  No significant changes 
were seen in cyclin E and B levels.  Interestingly, RAD001 suppressed the expres-
sion of c-jun in Fah-/- and Fah/p21-/- mice that were off NTBC, in which the prolifera-
tion was inhibited. In contrast, c-jun levels were markedly higher in RAD001-treated 
Fah/p53-/- mice that were off NTBC, in which proliferation was not completely inhib-
ited (figure 29). 
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Figure 29  Levels of several cell cycle-related proteins in Fah/p53-/- mice 
RAD001 or placebo was administered to Fah/p53 -/- mice for 14 days after 
NTBC withdrawal.  Immunoblots showing the expression of designed pro-
teins. 
 
 
To mediate proliferation, Rb activity is regulated during cell-cycle progression. Mito-
genic signaling cascades stimulate the activity of CDK complexes that phosphory-
late Rb. This phosphorylation attenuates the interaction of Rb with E2F family 
members.  Thus, as cells progress through cell cycle, Rb-mediated repression is 
alleviated.  In Fah-deficient mice taken off NTBC, Rb was activated.  Interestingly, 
treatment with RAD001 significantly reduced phosphorylation of Rb in those mice 
(figures 27-29). 
 
Next, cell cycle related proteins were analyzed in RAD001 and placebo-treated mice 
following partial hepatectomy.  Levels of cyclin D1 increased 24h after partial 
hepatectomy in placebo-treated mice. However, the expression of cyclin D1 was 
significantly delayed in RAD001-treated mice.  Additionally, cyclin E and A protein 
levels were diminished in RAD001-treated mice when compared with placebo-
treated C57BL/6 mice.  Similar to Fah-deficient mice, no significant changes were 
seen in cyclin B levels (figure 30).  Expression of c-jun, which peaked at 6h in pla-
cebo-treated mice, was significantly delayed in RAD001-treated mice (figure 30) 
where the hepatocyte proliferation was also delayed.  
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Figure 30  RAD001 affects the expression levels of several proteins re-
lated to cell cycle 
Liver extracts from C57BL/6 mice after partial hepatectomy were prepared 
and representative samples were subjected to Western Blotting using the 
indicated antibodies.  
 
 
As showed above, p21 expression is reduced by treatment with RAD001 in contrast 
to p27 levels that were only moderately affected by RAD001.  In order to analyze 
the effect of RAD001 on p27 and CDK-cyclin complexes, immunoprecipitation stud-
ies were performed with Fah-deficient mice.   
 
Immunobloting of p27 and cyclin E immunocomplexes showed high levels of CDK-
cyclin complexes in Fah-/-, Fah/p21-/-and Fah/p53-/- mice that were taken off NTBC.  
However, treatment with RAD001 considerably disturbed the interaction of p27 with 
CDK2, CDK4 and cyclin E in those mice (figure 31), suggesting that RAD001 inhib-
its factors involved in transition from the G0 phase to the G1 phase in the cell cycle.   
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Figure 31  Immunobloting of p27 and cyclin E immunocomplexes in 
Fah-deficient mice 
Analysis of the expression level of CDK2 and CDK4 in Fah-/-, Fah/p21-/- and 
Fah/p53-/- mice that were taken off NTBC. p27 and cyclin E were immuno-
precipitated from liver extracts, and the amount of bound CDK4, CDK2 or 
p27 was determined by Western Blotting. 
 
 
Additionally, when RAD001 was given 10, 20 or 30 hours after partial hepatectomy 
to wild-type mice, it only showed an antiproliferative effect 10 hours after surgery. 
Hepatocytes that already passed the early G0/G1 restriction point were no longer 
responsive to RAD001, and similar to placebo-treated mice, livers displayed many 
BrdU and Ki67 positive hepatocytes (figure 32).  Taken together, RAD001 treatment 
regulates the interaction of p27 with CDK-cyclin complexes, preventing cell-cycle 
progression from the G0/G1 phase into the S-phase. 
 
 
Figure 32  Hepatocytes that already passed the early G0/G1 restriction 
point were no longer responsive to RAD001 
RAD001 was given to C57BL/6 mice at 10, 20 or 30h and harvested at 36h 
after partial hepatectomy. Proliferation rates were analyzed by Ki67 and 
BrdU labelling. 
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4.6 RAD001 more effectively inhibits proliferation of hepa-
tocytes with DNA damage 
To confirm the observation that RAD001 more effectively prevents proliferation of 
damaged instead of healthy hepatocytes, wild type hepatocytes were transplanted 
into Fah/p21-/- mice after NTBC withdrawal and treated either with RAD001 or pla-
cebo. This approach permit to analyze the effect of RAD001 on healthy, trans-
planted WT hepatocytes and on damaged Fah/ p21-/- recipient hepatocytes in same 
mouse.  
 
Three months after transplantation, the livers were normal in shape and size. Then, 
cell proliferation and apoptosis were analysed by BrdU incorporation and TUNEL 
staining respectively.  BrdU staining revealed several positive cells, but no TUNEL-
positive hepatocytes were detectable in livers of transplanted RAD001-treated 
Fah/p21-/- mice (figure 33).  Fah immunostaining showed that more than 60% of the 
liver parenchyma was re-populated with WT Fah-positive transplanted hepatocytes 
(figure 33).  Interestingly, however, almost all BrdU positive cells were also positive 
for Fah in RAD001-treated mice in contrast with placebo-treated mice, in which 
BrdU positive cells were both Fah-negative and Fah-positive (figure 33).   
 
 
Figure 33  RAD001 inhibits, more effectively, the proliferation of hepa-
tocytes with DNA damage 
Wild-type hepatocytes were transplanted to Fah/p21-/- mice and treated for 3 
months with RAD001 after NTBC withdrawal.  Representative H&E staining 
and immunohistochemical detection of Fah are shown. Proliferation and 
apoptosis were determined by BrdU and TUNEL staining. Proliferating hepa-
tocytes in RAD001 treated livers are Fah-positive. 
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Subsequently, phosphorylation levels of S6, 4E-BP1 and Akt were determined. In 
Fah/p21-/- mice that were on NTBC, only 4E-BP1 phosphorylation was detected.  
After NTBC withdrawal, S6 phosphorylation was significantly increased, which was 
totally suppressed after RAD001 treatment in both groups, transplanted and control 
mice; contrary, no changes in 4E-BP1 levels were seen (figure 34).   
 
 
Figure 34  4E-BP1 and phosphorylation of S6 and Akt levels in Fah/p21-
/-
-transplanted mice 
Immunoblots showing the protein levels of 4E-BP1, phospho-S6 and phos-
pho-Akt from total liver lysates.   Positive control for phospho-Akt: Total liver 
lysate from insulin-injected mice. TX: transplanted mice. 
 
 
Additionally, levels of cyclin D1 were high in RAD001-treated transplanted mice; in 
contrast, c-jun was not detectable (figure 35).  Altogether, these data confirm that 
RAD001 treatment more effectively inhibits proliferation of hepatocytes with DNA 
damage. 
 
 
Figure 35  Cyclin D1 and c-jun levels in Fah/p21-/--transplanted mice 
Immunoblots showing the protein levels of cyclin D1 and c-jun from liver lys-
ates.  TX: transplanted mice. 
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4.7 RAD001 sustains apoptosis sensitivity in hepatocytes 
during chronic liver injury 
Previously, it has been shown that Fah-deficient mice develop a profound resis-
tance against apoptosis following NTBC withdrawal (Vogel et al., 2004). On the 
other hand, several reports have shown that rapamycin and its analogues enhance 
apoptosis sensitivity in tumor cells (Beuvink et al., 2005).  In this study, apoptosis 
was analysed by TUNEL staining.  As expected, almost no apoptotic hepatocytes 
were detected in Fah-/- mice that were taken off NTBC.  In contrast, Fah/p21-/- and 
Fah/p53-/- mice exhibited an increased number of apoptotic hepatocytes, which was 
not significantly changed in mice that were treated with RAD001 (figure 36A,B). 
 
 
 
Figure 36  TUNEL staining in Fah-/-, Fah/p21-/- and Fah/p53-/- mice after 
NTBC withdrawal 
Fah-/-, Fah/p21-/- and Fah/p53-/- mice were treated either with RAD001 or pla-
cebo for 14 days after NTBC withdrawal. TUNEL staining was performed in 
liver sections. Positive cells were counted in an x200 magnification. Average 
± SD is shown. 
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To investigate in more detail weather mTOR plays a role for the regulation of apop-
tosis during chronic liver injury, Fah-/- mice were taken off NTBC, treated with either 
RAD001 or placebo for 14 days and then challenged with the mAb Fas to induce 
hepatocellular apoptosis. Liver tissue from Fah-/- mice that were on NTBC and 
treated with mAb Fas displayed severe hepatocyte destruction and massive hemor-
rhage.  Additionally, TUNEL staining revealed multiple positive cells (figure 37).   In 
contrast, Fah-/- mice that were off NTBC and treated with mAb Fas, although some 
tissue damage is revealed, no TUNEL positive cells were detectable (figure 37). 
When Fah-/- mice that were off NTBC treated with RAD001 were challenged with 
mAb Fas, a fulminant liver failure occurred similar to Fah-/- mice that were on NTBC 
(figure 37).   
 
 
Figure 37 RAD001 sustains apoptosis sensitivity in hepatocytes during 
liver injury 
Hepatocellular apoptosis was induced by mAb Fas injection in Fah-/- mice af-
ter 14 days of RAD001 treatment and NTBC withdrawal. H&E staining 
showed disruption of liver tissue in mAb Fas-injected mice. TUNEL positive 
hepatocytes were observed in RAD001-treated livers in contrast to the pla-
cebo treated mice.  
 
 
According to the results showed above, there was no caspase-3 activity, and very 
strong activation was seen in Fah-/- mice that were on NTBC before and after induc-
tion of apoptosis by mAB Fas injection (figure 38); as expected, caspase-3 activity 
was diminished after NTBC withdrawal.  Additionally, treatment with RAD001 sus-
tained the apoptosis sensitivity in Fah-/- mice that were taken off NTBC. 
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Figure 38  Measurement of caspase-3 activity in Fah-/- mice 
Caspase activity was determined in control and mAb Fas-challenged mice 
(closed bars: on NTBC; open bars: off NTBC).  (F.0: control, F.4: mAb Fas 
injected mice and scarified after 4h; *p≤0.0001). 
 
 
In concordance with the data from histology and caspase-3 activity, cleavage of Bid 
and caspase-9 were seen in Fah-/- mice that were on NTBC and RAD001-treated 
Fah-/- mice that were off NTBC, after mAb Fas injection (figure 39).  Together these 
data indicate that treatment with RAD001 sustains the apoptosis sensitivity in hepa-
tocytes with DNA damage. 
 
 
Figure 39  Cleavage of caspase-9 and Bid expression 
Cleavage of caspase-9 and Bid were measured in liver extracts by Western 
blotting.  (F.0: control, F.4: mAb Fas-injected mice and scarified after 4h). 
 
 
To better understand the mechanism by which RAD001 sustains apoptosis sensitiv-
ity in Fah-deficient mice, some apoptosis-related proteins were analyzed by West-
ern Blotting.  In Fah-/- mice that were on NTBC, no significant changes were seen in 
the most analyzed proteins in RAD001 and placebo-treated mice; Bim was not de-
tected in those mice.  After NTBC withdrawal, levels of Fas receptor were slightly 
increased in RAD001-treated Fah-/- mice that were off NTBC when compared with 
placebo-treated mice.  Expression of the inhibitor of caspase-8, Flip-s, was reduced 
in apoptosis resistant Fah-/- mice that were off NTBC; however, levels were restored 
under RAD001 treatment. An increased expression of anti-apoptotic members of 
the Bcl-2 family, Bcl-xL and Mcl-1, was seen in both Fah-/- RAD001 and placebo-
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treated mice after NTBC withdrawal. Bim and Bid levels, pro-apoptotic proteins, 
were also increased in Fah-/- mice after NTBC withdrawal. Treatment with RAD001 
reduced the levels of Bim in Fah-/- mice that were taken off NTBC but not Bid levels. 
Expression levels of cIap1, an endogenous inhibitor of caspases, were not signifi-
cantly changed (figure 40).   
 
 
Figure 40  Analysis of pro- and anti-apoptotic proteins in RAD001 or 
placebo treated Fah- /- mice 
Liver extracts were isolated, and representative samples (2 mice per group) 
were subjected to Western Blotting using the indicated antibodies. 
(Pla.:Placebo, RAD: RAD001). 
 
 
Furthermore, absence of p21 and p53 did not influence the expression of the ana-
lyzed proteins in comparison to Fah-/- mice; only the expression of Flip-s was 
changed: reduced in Fah/p21-/- and increased in Fah/p53-/- mice, and taken off 
NTBC (figure 41).  The most consistent effect of RAD001 treatment on apoptosis-
related proteins was the reduced expression of pro-apoptotic protein Bim in all three 
mouse lines following NTBC withdrawal. However, none of the analyzed proteins 
correlated with the sensitivity/resistance to apoptosis in Fah-/- mice.  
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Figure 41  Analysis of pro- and anti-apoptotic proteins in RAD001 or 
placebo-treated Fah/p21-/- and Fah/p53-/- mice 
Liver extracts were isolated, and representative samples (2 mice per group) 
were subjected to Western Blotting using the indicated antibodies. 
(Pla.:Placebo, RAD: RAD001). 
 
 
4.8 Long-term treatment with RAD001 delays liver tumor 
development 
All data presented above show that treatment with RAD001 specifically inhibits pro-
liferation of damaged hepatocytes and sustains the apoptosis hepatocyte sensitivity 
during chronic liver injury. The next question to address was whether long-term 
treatment with RAD001 delays tumor development in the liver.  Therefore, Fah/p21-/- 
mice were taken off NTBC and treated daily with either RAD001 or placebo for 4 
months.  Fah/p21-/- mice were used because they have an accelerated hepatocyte 
proliferation and develop liver tumors within 3 months, which is significantly faster 
than in Fah-/- mice (Willenbring et al., 2008b).  At the end of the experiment, body 
weight was similar in RAD001 and placebo-treated mice (figure 42A). In contrast, 
liver weight of placebo-treated mice was almost two times higher than livers from 
RAD001-treated mice; this difference was due to the presence of multiple tumors in 
the placebo-treated mice (figure 42B).  
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Figure 42  Fah/p21-/- mice were treated with RAD001 or placebo for 4 
months after NTBC withdrawal 
A Body weights of RAD001 and placebo-treated mice. B Livers from pla-
cebo-treated mice were significantly bigger than those from RAD001-treated 
mice (*p≤0.0001). 
 
 
In addition, transaminase levels were also significantly higher in RAD001-treated 
mice (figure 43), suggesting that treatment with RAD001 did not ameliorate overall 
liver injury in Fah/p21-/- mice that were taken off NTBC.  
 
 
Figure 43  Transaminase levels of long term RAD001 and placebo-
treated Fah/p21-/- mice 
Increased levels of ALT were found in RAD001-treated mice (*p≤0.0001). 
 
 
All animals treated with placebo developed multiple and large tumors. Treatment 
with RAD001 significantly delayed tumor onset and progression (figure 44).  In 40% 
of RAD001-treated mice, no macroscopic visible tumors were detected, 30% dis-
played a granular liver surface and 30% minimal tumor nodules were visible.  
Analysis of liver histology showed a severe hepatitis in all mice that is also con-
firmed by ALT levels, which are higher in RAD001-treated mice (figures 43, 45). 
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Figure 44  Long-term treatment with RAD001 significantly delays tumor 
development in the liver 
Fah/p21-/- mice were treated with either RAD001 or placebo for 4 months af-
ter NTBC withdrawal. Liver pictures showing the anti-proliferative effect of a 
long-term RAD001 treatment.  
 
 
In order to investigate the mechanism by which RAD001 delays tumor formation in 
the liver, analysis of proliferation and apoptosis was performed.  BrdU incorporation 
was used to determined cell proliferation. BrdU immunohistochemistry revealed 
multiple positive hepatocytes in Fah/p21-/- placebo-treated mice in contrast with 
RAD001-treated mice where hepatocyte proliferation was markedly inhibited (figure 
45). However, many small- and oval-shaped cells were BrdU-positive in RAD001-
treated livers. When the ability of hepatocyte regeneration is compromised, a sub-
population of liver cells is induced to proliferate. These oval cells --termed so due to 
their oval shape, ovoid nucleus and small size (compared with hepatocytes)-- prolif-
erate in the periportal region of the liver and, as liver damage progresses, they infil-
trate into the parenchyma along the bile canaliculi between the hepatic cords. In this 
study, immunodetection of oval cells by A6 staining revealed a significantly higher 
number of positive cells in Fah/p21-/- RAD001-treated mice than in placebo-treated 
mice. Additionally, TUNEL staining was used to determine apoptosis.  Several 
TUNEL-positive cells were seen in both groups (figure 45), indicating that RAD001 
treatment did not alter apoptosis in Fah/p21-/- mice that were taken off NTBC. 
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Figure 45  Liver histology of long-term RAD001-treated Fah/p21-/- mice 
Representative H&E staining, analysis of apoptosis, proliferation and immu-
nohistochemical detection of the levels of A6 are shown. 
 
 
At the end of the experiment, placebo-treated Fah/p21-/- mice displayed low levels of 
4E-BP1, S6 and Akt phosphorylation (figure 46).  However, long-term treatment with 
RAD001 suppressed phosphorylation of S6, did not induce a sustaining activation of 
Akt and did not affect the expression of eIF-4E. 
 
 
Figure 46  Expression of 4E-BP1 and eIF-4E and phosphorylation levels 
of S6 and Akt in long-term RAD001-treated Fah/p21-/- mice 
Fah/p21-/- mice were treated with RAD001 or placebo for 4 months after 
NTBC withdrawal.  Liver extracts were isolated, and representative samples 
were subjected to Western Blotting using the indicated antibodies (The first 
two lanes are protein samples from 15 days RAD001-treated mice; 
Pla.:Placebo, RAD: RAD001). 
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Additionally, cyclin A, E and c-jun were almost not detectable in placebo-treated 
Fah/p21-/- mice.  In contrast, the expression of cyclin D1 and eIF-4E was seen in 
those mice (figures 46, 48).  Interestingly, RAD001-treated mice presented higher 
levels of cyclin D1, cyclin A, cyclin E and c-jun than in placebo-treated mice (figure 
47).  Altogether, these data show that RAD001 delays tumorigenesis mainly by in-
hibiting proliferation of damaged hepatocytes rather than by inducing apoptosis. 
Surprisingly, several cell-cycle related proteins were up-regulated in mice that were 
treated for 4 months in comparison with mice that were treated for 14 days, with 
RAD001. 
 
 
Figure 47  Expression of several cell-cycle related proteins in long-
term RAD001-treated Fah/p21-/- mice 
Fah/p21-/- mice were treated with RAD001 or placebo for 4 months after 
NTBC withdrawal.  Liver extracts were isolated, and representative samples 
were subjected to Western Blotting using the indicated antibodies (The first 
two lanes are protein samples from 15 days RAD001-treated mice; 
Pla.:Placebo, RAD: RAD001). 
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5 Discussion 
Rapamycin was approved as an immunosuppressive drug in 1999 and, since then, 
has been used for preventing allograft rejection. Although rapamycin was shown to 
possess anti-tumor properties over 20 years ago (Eng et al., 1984), it was never 
taken forward for cancer patients.  However, as more information on the role of 
mTORC1 in human tumors, including hepatic tumors, has emerged, the application 
of rapamycin for this indication is being reevaluated.  Modified versions of rapamy-
cin, such as RAD001, are currently in various stages of clinical trials.  Therefore, the 
purpose of the present study was to determine how RAD001 affects proliferation 
and apoptosis of non-transformed hepatocytes during chronic liver disease. The 
findings show that treatment with RAD001 did not significantly reduce FAA-induced 
hepatocyte injury.  Additionally, RAD001 treatment effectively inhibits proliferation of 
hepatocytes with DNA damage and sustains their apoptosis sensitivity during 
chronic liver injury. Interestingly, long-term treatment with RAD001 markedly delays 
liver tumor development in Fah/p21-/- mice. 
 
5.1 Effect of RAD001 on hepatocyte growth and prolifera-
tion 
mTOR is involved in several pathways including control of cell proliferation, regula-
tion of ribosomal biogenesis and induction of the protein translation apparatus.  In 
vitro studies have shown that rapamycin suppresses tumor growth by arresting the 
cell cycle in the G1 phase (Decker et al., 2009; Wendel et al., 2004).  To better un-
derstand the role of mTOR in hepatocarcinogenesis and on hepatocyte proliferation 
and apoptosis, the effect of RAD001 in the mouse model for HT1 was analyzed.  
HT1 is characterized by an extremely high susceptibility for liver cancer.  After 
RAD001 treatment, the baseline proliferation of healthy hepatocytes was not af-
fected, but the proliferation of hepatocytes with DNA damage was markedly sup-
pressed.  In addition, RAD001 induced cell-cycle arrest in Fah/p21-/- mice that were 
taken off NTBC where many proliferating hepatocytes were seen; in contrast, 
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RAD001 did not completely arrest the cell cycle in Fah/p53-/- mice that were taken 
off NTBC. 
  
For a cell to proliferate, it must up-regulate the biosynthesis apparatus needed to 
support cell growth.  Several studies have shown that the mRNA transcripts for all 
ribosomal protein and protein synthesis elongation factors contain an unusual oli-
gopyrimidine tract, referred to as 5’TOP.  The translation of these mRNA transcripts 
is dependent on S6K1 activation and mediated by an increase of S6 phosphoryla-
tion (Jefferies et al., 1994).  In vitro, it has been demonstrated that the activation 
either of S6K1 or 4E-BP1/eIF-4E pathways partially rescues the inhibitory effect of 
rapamycin on G0 to S phase cell-cycle progression.  Additionally, S6K1 and 4E-
BP1/eIF-4E pathways independently regulate mTOR-dependent cell-cycle control in 
parallel, and a simultaneous downregulation of these two pathways result in an ad-
ditive arrest of cell-cycle progression in the G1 phase compared to downregulation 
of the pathways individually, indicating in some sense that these represent the two 
major pathways that control cell cycle in an mTOR-dependent manner (Fingar et al., 
2004).   
 
In rats, it has been shown that partial hepatectomy induces a transient increase of 
S6K1 activity in the liver, when compared with sham-operated animals.  The amount 
of S6K1 does not increase, but the active kinase shows high phosphorylation levels.  
Additionally, rapamycin blocks the activation of S6K1 in response to partial hepatec-
tomy in a dose-dependent manner (Jiang et al., 2001).  Several studies have shown 
that the effect of rapamycin in hepatocyte proliferation is comparable to inhibition of 
S6K1 and S6 phosphorylation.  A research group has shown that adult mouse livers 
that have a conditionally deleted S6 gene failed to regenerate after two-thirds partial 
hepatectomy; this lesion in cell proliferation does not seems to result from a lack of 
translational capacity, because no difference in the abundance or rate of accumula-
tion of p21 or cyclin D1 protein in S6-deficient versus wild-type liver cells was ob-
served. Moreover, they showed that S6-deficient liver cells have the ability to syn-
thesize proteins and grow. The failure to progress to the S phase in the cell cycle 
appeared to be due to a block in expression of cyclin E mRNA (Volarevic et al., 
2000).  According to these findings, in this study, it was seen that treatment with 
RAD001 strongly suppressed S6 phosphorylation in livers from Fah-/-, Fah/p21-/- and 
Fah/p53-/- and WT mouse livers.  However, this effect showed a dissociation be-
tween S6 phosphorylation and proliferation of hepatocytes.  Several BrdU-positive 
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hepatocytes were seen in Fah/p53-/- and long-term RAD001-treated Fah/p21-/- mice 
and in WT livers after 72h partial hepatectomy and RAD001 treatment despite the 
sustained inhibition of S6 phosphorylation.  Thus, these results show that S6 is a 
good biomarker to control mTOR inhibition but it is not reliable in controlling hepato-
cyte proliferation. 
 
It has been shown that phosphorylation of S6 and hepatocyte proliferation does not 
always match. In rats, the basal hepatic S6K1 activity in the late gestation-fetal 
phase is lower than that in adult animals.  However, this period is characterized by a 
high rate of hepatocyte proliferation, showing a discrepancy between cell prolifera-
tion and activity of this enzyme.  Additionally, when rapamycin was administrated to 
fetal hepatocytes, cell proliferation could proceed even though S6 phosphorylation 
was markedly decreased, suggesting that fetal hepatocytes utilize an alternative, 
rapamycin-resistant pathway for DNA synthesis and proliferation (Boylan et al., 
2001).  Previous studies have shown the existence of S6-independent mechanisms 
for 5’TOP mRNA translation: S6K1 knockout murine embryonic stem cells do not 
show any S6 phosphorylation; however, 5’TOP mRNAs were detected in polysomal 
fractions, indicating active eukaryotic elongation factors.  Consistent with these re-
sults, RAD001-inhibited phosphorylation of S6 in hepatic progenitor cells, failed to 
inhibit proliferation of these cells in long-term treated Fah/p21-/- mice, suggesting 
that mTOR inhibition specifically affects proliferation of adult hepatocytes, inde-
pendent of S6 phosphorylation. 
 
In contrast to inhibition of S6 phosphorylation in Fah-deficient and WT mice, treat-
ment with RAD001 moderately affected the phosphorylation of 4E-BP1.  It has been 
shown that partial hepatectomy leads to a substantial increase in 4E-BP1 phos-
phorylation: from the ß specie to the most phosphorylated form, γ.  However, and in 
agreement with this study, when rapamycin was given to the mice that underwent 
partial hepatectomy, the phosphorylation of 4E-BP1 was not significantly changed.  
Another study showed that 4E-BP1 phosphorylation was not reduced in rapamycin-
treated rats as compared with the controls after partial hepatectomy; the ratio of the 
γ band to the total amount of 4E-BP1 appeared to slightly increase at higher doses 
of rapamycin, indicating that 4E-BP1 might be more phosphorylated in rapamycin-
treated animals than in controls (Jiang et al., 2001).  Additionally, eIF-4E/eIF-4G 
complex assembly was induced in the regenerating mouse livers; however, this 
complex was disturbed after RAD001 treatment (Goggin et al., 2004).  This sug-
Discussion 
 87  
gests that phosphorylation of 4E-BP1 plays a minor role in mediating the effects of 
mTOR on mitogen-stimulated hepatocyte proliferation. Thus, additional downstream 
targets of mTOR are probably involved in regulation of proliferation of hepatocytes. 
 
It has been shown that a negative feedback loop exists between S6 kinase and in-
sulin receptor substrate-1 (IRS1) that activates Akt kinase following suppression of 
mTORC1 (Guertin and Sabatini, 2007).  In contrast, no activation of Akt kinase was 
seen in Fah-deficient mice after RAD001 administration. However, when Fah/p21-/- 
mice were treated for a long time, an activation of Akt kinase was detected.  It has 
been demonstrated that rapamycin can induce Akt phosphorylation in tumors, im-
plying that its potential antitumor activity is attenuated by the release of feedback 
inhibition of growth signaling pathways. This suggests that combined inhibition of 
constitutively activated oncoproteins and of normal pathways that are down-
regulated by oncoprotein-inhibition may be much more effective combined than 
alone. For example, combination therapy with an mTOR inhibitor and an inhibitor of 
the growth factor receptor, such as IGF-IR, that normally drives PI3K activity in that 
tumor, might also be a promising combination therapy (O'Reilly et al., 2006). 
 
Increased protein synthesis is one of the major anabolic events required for the 
growth response.  Studies suggest that one of the key points upon which signaling 
pathways converge to regulate growth is the mTOR signaling pathway: mTOR is an 
important regulator of translational initiation (Fingar et al., 2002; Gingras et al., 
2001b; Schmelzle and Hall, 2000; Thomas and Hall, 1997).  This pathway controls 
phosphorylation of 4E-BP1, releasing its inhibitory interaction with eIF-4E, allowing 
eIF-4E to associate with eIF-4G to form the active eIF-4F complex, a necessary 
component of the 40S initiation complex. eIF-4E activity appears to be particularly 
important for the translation of mRNAs containing a highly structured 5' untranslated 
region, such as transcripts encoding many proteins associated with growth and pro-
liferation control (Gingras et al., 2001a; Gingras et al., 2001b; Sonenberg and Gin-
gras, 1998; West et al., 1998).  Additionally, eIF-4E levels are limited for cap-
dependent translation in most systems, and over-expression of eIF-4E in rodent 
cells causes malignant transformation (Lazaris-Karatzas et al., 1990; Mamane et 
al., 2004).  Several studies demonstrated that eIF-4E acts as an oncogene  
(Mamane et al., 2004).  Therefore, increased eIF-4E expression in cancer cells is 
thought to enhance eIF-4F complex formation, and as a consequence, the transla-
tion of a subset of mRNAs that contains highly structured 5' untranslated regions, 
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such as vascular endothelial growth factor (VEGF). Indeed, eIF-4E is elevated in 
numerous types of cancers, including HCC (De Benedetti and Graff, 2004).  Fur-
thermore, the importance of eIF-4E's role in tumorigenesis is reinforced by the find-
ing that the eIF-4F complex is necessary for maintaining tumor cell growth (Avdulov 
et al., 2004).  Importantly, siRNA treatment to reduce eIF-4E expression inhibits the 
growth of several cell lines including those of head and neck squamous carcinoma 
cells (Oridate et al., 2005).  To better understand how mTOR regulates hepatocytes 
proliferation, the effect of RAD001 on protein translation was analyzed in three dif-
ferent experimental systems: mitogen-stimulated proliferation of damaged hepato-
cytes during liver injury, mitogen-stimulated proliferation of healthy hepatocytes af-
ter partial hepatectomy and nutrient-induced growth after a period of fasting.  Levels 
of eIF-4E were slightly upregulated in Fah-deficient mice. However, treatment with 
RAD001 did not significantly affect its expression. In fact, RAD001 fails to inhibit 
eIF-4F assembly and to reduce the translation-dependent accumulation of onco-
genic proteins in mammalian cells (Beretta et al., 1996; Jefferies et al., 1994; Tam-
burini et al., 2009).  Additionally, no significant changes were seen in this study in 
the expression of the translation initiation factors following RAD001 treatment.  In-
terestingly however, treatment of mice during re-feeding after a period of starvation 
revealed that RAD001 slightly, but significantly, inhibited global protein synthesis in 
the liver. Similarly, treatment with the drug results in a small decrease in overall pro-
tein synthesis in most cell lines, which might contribute to the inhibition of prolifera-
tion.   
 
Most cells are arrested specifically in the G1 phase of the cell cycle following rapa-
mycin treatment. Therefore, several cell-cycle related proteins and their inhibitors 
were analyzed.  As showed in previous studies, p21 levels were increased after 
NTBC withdrawal (Willenbring et al., 2008a) and were reduced after RAD001 treat-
ment (Beuvink et al., 2005).  However, in S6-deficient hepatocytes, the expression 
of cyclin D, p21 and p27 does not change after partial hepatectomy when compared 
with their control counterparts.  Here, expression of p27 was not significantly af-
fected in RAD001-treated mice.  Additionally, S6-deficient hepatocytes show no in-
duction of cyclin E and A after partial hepatectomy (Volarevic et al., 2000).  In Fah-
deficient mice, RAD001 treatment not only affected the expression of cyclin E and A 
but also the expression of cyclin D and c-jun.  However, RAD001 did not affect the 
cyclin A expression in Fah/p53-/- mice. Similarly, previously, it has been shown that 
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cyclin A levels were reduced to a very low level by rapamycin in wild-type cells but 
remained high in cells lacking p53 (Huang et al., 2001). 
 
Several studies have shown that cyclin D is overexpressed in different cancer types, 
including HCC, and that its overexpression could contribute to tumor development. 
However, cyclin D expression is downregulated by rapamycin in some cell types.  
Nevertheless, when cyclin D is constitutively expressed, it contributes to malignant 
transformation by reducing the dependence on extracellular signals that normally 
control proliferation, leading to a reversion of rapamycin-induced cell-cycle arrest, 
suggesting that cyclin D is an important mediator of proliferation, downstream of 
mTOR (Nelsen et al., 2003).   
 
However, cyclin D levels are not reduced in all cells that display inhibition of prolif-
eration. Some studies show that rapamycin induces cell-cycle arrest in the G1 
phase, but the levels of cyclin D were not affected in human cell lines. Contrary to 
the findings from this study, it has also been shown that rapamycin failed to inhibit 
cell-cycle progression in cells lacking p21, indicating that rather than cyclin D, p21 is 
most important in cell-cycle regulation through mTOR (Huang et al., 2001).  Another 
study showed that rapamycin inhibits cell proliferation by destabilizing the CDK2-
cyclin D-p21-PCNA complexes in cell cycle suggesting that cyclin D and p21 func-
tion together in order to inhibit cell-cycle progression (Law et al., 2006).  In this 
study, it was seen a correlation between downregulation of cyclin D expression and 
inhibition of hepatocyte proliferation in Fah-/- and Fah/p21-/- after RAD001 treatment 
and NTBC withdrawal. Contrary to these observations, expression of cyclin D was 
reduced in Fah/p53-/- mice that were off NTBC in which the hepatocyte proliferation 
was not completely suppressed.   
 
Interestingly, fetal hepatocytes in late gestation demonstrate a high rate of prolifera-
tion that is not inhibited by rapamycin or dependent on S6 phosphorylation (Boylan 
et al., 2001).  The fetal hepatocytes express significant amounts of cyclin D and ap-
pear to proliferate in a mitogen-independent manner (Awad et al., 2000; Awad and 
Gruppuso, 2000), suggesting that the expression of cyclin D, which is induced in 
fetal hepatocytes through pathways distinct from those observed in adult cells 
(Awad and Gruppuso, 2000), promotes rapamycin resistance (Nelsen et al., 2003).  
In agreement with these observations, increased levels of cyclin D were seen in 
Fah/p21-/- mice after long-term treatment with RAD001.  Therefore, estimation of 
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cyclin D levels is not a reliable marker for predicting cellular response under 
RAD001 treatment.  Additionally, the results in Fah/p21-/- mice clearly indicate that 
the effect of RAD001 on hepatocyte proliferation is independent of p21.  
 
Some studies have show that c-jun is a critical regulator of hepatocyte proliferation 
and survival during liver regeneration (Behrens et al., 2002; Eferl et al., 2003).  
Here, expression levels of c-jun were downregulated in RAD001-treated Fah-/- and 
Fah/p21-/- mice after NTBC withdrawal in which hepatocyte proliferation was inhib-
ited.  Nevertheless, a high expression of c-jun in RAD001-treated Fah/p53-/- mice 
that were taken off NTBC was seen in which hepatocyte proliferation was reduced 
but not totally inhibited. Furthermore, Fah/p21-/- mice --that were treated long-term 
treated with RAD001-- showed high levels of c-jun, correlating with the fact that pro-
liferation was only attenuated in those mice.  Additionally, c-jun expression was de-
layed in RAD001-treated mice after partial hepatectomy in which hepatocyte prolif-
eration was also delayed. Moreover, RAD001 and placebo-treated Fah-/-/c-junfl/fl/mx-
cre mice, in which c-jun was conditionally deleted in hepatocytes, displayed a similar 
number of proliferating hepatocytes 72 hours after partial hepatectomy, suggesting 
that cell-cycle progression occurs independently of c-jun (data not shown). How-
ever, the data from this study suggest that mTOR regulates c-jun expression during 
hepatocyte proliferation.  
 
Several studies have shown that the mTOR and p53 pathway communicate with 
each other. Activation of p53 by a physiological relevant stress signal, DNA dam-
age, inhibits mTOR activity in normal cells, the primary MEFs. A similar inhibition of 
mTOR activity in human cancer cells was observed after the activation of a tem-
perature-sensitive mutant of p53.  This regulation of mTOR by p53 is independent 
of the cell-cycle regulation by p53, because p53 regulates mTOR in p21-/- MEFs as 
well as it does in WT MEFs (Feng et al., 2005).  A strong activation of the p53/p21 
pathway occurs in Fah-deficient mice after NTBC withdrawal (Willenbring et al., 
2008a).  After RAD001 treatment, levels of p53 and p21 were significantly lower in 
Fah-/- and Fah/p21-/- mice than in the controls, suggesting that activation of mTOR 
during chronic liver injury contributes to p53 accumulation in hepatocytes.  Addition-
ally, it has been shown that cells with constitutive mTOR activation decreased p53 
levels after treatment with rapamycin and following DNA damage (Lee et al., 2007).  
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Studies suggested that rapamycin inhibits cell-cycle progression independently of 
p53 (Metcalfe et al., 1997). Additionally, other studies suggested that rapamycin 
slowed but could not stop cell-cycle progression in p53 mutant tumor cell, leading to 
apoptosis (Huang et al., 2001).  However, the effect of RAD001 on hepatocyte pro-
liferation and on c-jun protein expression was markedly attenuated in p53 null mice. 
Therefore, these data suggest that loss of p53 decreases the ability of hepatocytes 
to arrest before the S-phase in response to RAD001 treatment.  However, the exact 
mechanism by which cells arrest in G1 due to activation of mTOR and p53 path-
ways remains to be explored.   
 
p21 and p27 serve as assembly factors for CDK complexes. Rapamycin downregu-
lates p21 levels; however, no effect of rapamycin in the levels of p27 was seen.  
This would suggest that rapamycin selectively disrupts CDK complexes that require 
p21 as an assembly factor but not those that require p27 as an assembly factor.  In 
vitro, disruption of CDK2-cyclin D1-p21-PCNA complexes correlates with rapamy-
cin-induced cell-cycle arrest, and this disruption correlated best with downregulation 
of cellular p21 levels.  Additionally, CDK2-cyclin D complexes are inactivated by ra-
pamycin treatment in a relatively selective manner through p21 downregulation in 
cells in vivo (Law et al., 2006).  It has been recently shown that rapamycin does not 
affect the amount of either CDK2 or cyclin E protein in the complex and that the 
amount of p27 coimmunoprecipitated with cyclin E increases in response to rapa-
mycin in tumorigenic hepatic cell lines (Jimenez et al., 2009).  In T cells, rapamycin 
inhibits CDK2-cyclin E kinase activity and increases the amount of p27 coimmuno-
precipitated with cyclin E.  In this study, RAD001 treatment substantially inhibited 
phosphorylation of Rb in Fah-/- and Fah/p21-/- mice that were off NTBC indicating 
that the drug affected activation of CDK-cyclin complexes. Interestingly however, 
the immunoprecipitation studies presented here showed that treatment with 
RAD001 did not induce CDK2-cyclin E-p27 complexes but rather inhibited the for-
mation of CDK-cyclin complexes. Altogether, these data suggest that RAD001 may 
inhibit Rb inactivation by multiple pathways and therefore inhibit cell-cycle progres-
sion. Importantly, it has been published that Rb plays a key role in tumorigenesis in 
the liver, compromising hepatocyte proliferation and genome integrity. Evaluation of 
Rb status may be a useful prognostic factor in human HCC (Mayhew et al., 2007). 
 
The data presented above showed that RAD001 specifically inhibits factors facilitat-
ing the transition of cells from the G0 phase to the G1 phase of the cell cycle.  It has 
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been shown that rapamycin fails to inhibit the proliferation of the cells that already 
pass G1/S transition or are growing exponentially, suggesting that the antiprolifera-
tive effect of rapamycin might be cell-cycle phase-dependent (Kawamata et al., 
1998).  Accordingly, when WT mice, 20h after PH are treated with RAD001, the 
drug fails to inhibit cell cycle, indicating once more that RAD001 prevents progres-
sion into the S-phase only in cells that have not passed the G0/G1 restriction point 
in the cell cycle. 
 
5.2 Effect of RAD001 on hepatocytes apoptosis 
Dysregulation of the apoptosis pathways is a hallmark of cancer because mutations 
in apoptotic regulators invariably accompany tumorigenesis.  The mTOR pathway is 
involved in key events during apoptosis in cancer, and consequently, rapamycin has 
been associated with apoptosis induction in different tumor systems.  Previously, it 
has been shown that treatment with rapamycin affected only moderate activity in 
inducing apoptosis of cancer cells (Tam et al., 2009).  However, it has been shown 
that rapamycin specifically induced apoptosis independently of p53 in human rhab-
domyosarcoma cells.  In cells lacking p53, rapamycin induces rapid and sustained 
activation of apoptosis signal-regulating kinase 1 (ASK1), c-jun N-terminal kinase 
(JNK), and elevation of phosphorylated c-jun that results in apoptosis.  This effect is 
abrogated by ectopic overexpression of p21, with p21 binding to ASK1 and blocking 
JNK activation (Hosoi et al., 1999; Huang et al., 2003; Huang et al., 2004).  In this 
study, treatment with RAD001 induced only modestly hepatocellular apoptosis in 
Fah-deficient mice after NTBC withdrawal. 
 
In contrast, in combination therapy, rapamycin sensitizes cancer cells to apoptosis.  
It has been shown that rapamycin promotes cisplatin-induced apoptosis in wild-type 
p53, but not mutant p53 tumor cells, due to its ability to block p53-induced p21 ex-
pression (Beuvink et al., 2005).  In human ovarian cancer cell lines, rapamycin and 
carboplatin additively enhance apoptosis (Schlosshauer et al., 2009).  Moreover, 
when Ras and mTOR pathways are blocked by administration of sorafenib and ra-
pamycin to human HCC cell lines, apoptosis is significantly enhanced when com-
pared to sorafenib alone (Newell et al., 2009).  In additional to the combination ther-
apy, rapamycin reverses the chemoresistance in Akt-induced tumorigenesis by dis-
Discussion 
 93  
rupting the Akt signaling and sustaining apoptosis sensitivity in cancer cells (Wendel 
et al., 2004).  In this study, interestingly however, RAD001 treatment markedly sus-
tained the apoptosis sensitivity against Fas-induced apoptosis in Fah-deficient mice 
that were off NTBC.  
 
Previous studies show that rapamycin can affect the apoptosis sensitivity of tumor 
cells by regulating several pro- and anti-apoptotic proteins.  In a mouse model for 
lung cancer, it has been shown that rapamycin promotes apoptosis by up-regulating 
the pro-apoptotic protein Bid and Bax and down-regulating Bcl-xL (Yang et al., 
2009).  Furthermore, it has been shown that mTOR transcriptionally regulates FLIPs 
levels and controls the sensitivity of human glioma cells to apoptosis induced by the 
death ligand TRAIL.  The accumulation of FLIPs mRNA and FLIPs protein expres-
sion, which is overexpressed in many tumors, confers apoptosis resistance to can-
cer cells. TRAIL-induced apoptosis can be suppressed by activation of either the 
S6K1 or 4E-BP1 arms of the mTOR pathway, and inhibition of either arm sensitizes 
cells to TRAIL-induced apoptosis as effectively as mTOR inhibition by rapamycin 
(Panner et al., 2005).  Also, rapamycin can modulate expression of Mcl-1, an impor-
tant anti-apoptotic regulator (Mills et al., 2008).  However, the expression of several 
apoptosis-related proteins, analyzed in this study, was not regulated after RAD001 
treatment, revealing no consistent changes in apoptosis-sensitive and apoptosis-
resistance mice; only Bim, which is a major regulator of apoptosis in the lymphoid 
and liver, was slightly upregulated following NTBC withdrawal.    
In response to chemotherapy, p53 protein is stabilized and mediates apoptosis and 
cell cycle-arrest.  The mechanism of p53-dependent cell-cycle arrest is primarily 
mediated by p21.  However, there is evidence that p21 is a major inhibitor of p53-
dependent apoptosis.  It is unclear how a cell decides between apoptosis and p21-
dependent cell-cycle arrest after DNA damage and stabilization of p53.  It has been 
shown that high levels of p21 expression often mediate cell-cycle arrest and protect 
from p53-dependent apoptosis.  Additionally, p21 blocks apoptosis by interacting 
with proapoptotic molecules such as procaspase-3, caspase-8 and the kinase apop-
tosis signal-regulating kinase 1 (ASK1) (Gartel and Tyner, 2002).  Therefore, the 
sustained sensitivity against Fas-induced apoptosis might be related to the loss of 
p21 in Fah-deficient RAD001-treated mice that were taken off NTBC. 
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6 Conclusion 
Rapamycin and its analogues are tested as therapeutic agents for the treatment of 
different cancers due to their capacity to inhibit cell growth and proliferation.  Cur-
rently, RAD001 is in phase I study for dose escalation and in phase II study for in-
tent to treat, as well as pharmacokinetic, pharmacogenetic and surrogate marker 
study.  Prevention is the only realistic approach for reducing mortality rates associ-
ated with hepatocellular carcinoma worldwide.  Preventing the development of HCC 
is referred to as primary prevention.  Fortunately, the natural history of HCC pro-
vides many opportunities for an impact to be made on the occurrence of primary 
liver cancer because of its known association with chronic liver disease and cirrho-
sis.  The first opportunity involves the use of measures to avoid risk factors for HCC 
including viral infections and toxins.  The second is early recognition and treatment 
of acute and inherited liver diseases, which may block the transition to chronic dis-
ease.  The third is to prevent progression of chronic disease to cirrhosis. Finally, 
once cirrhosis is established, chemoprevention can interfere with the molecular 
events leading to HCC.  This study suggests that RAD001 should be clinically used 
as an effective chemopreventive agent in the liver.  The data presented here show 
that RAD001 specifically inhibits the proliferation of damaged hepatocytes and sus-
tains their apoptosis sensitivity during chronic liver injury.  Altogether, the mTOR 
inhibition might be recommendable as an effective strategy to delay hepatocarcino-
genesis in patients at risk.  
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